WO2022248858A1 - Formulation - Google Patents
Formulation Download PDFInfo
- Publication number
- WO2022248858A1 WO2022248858A1 PCT/GB2022/051328 GB2022051328W WO2022248858A1 WO 2022248858 A1 WO2022248858 A1 WO 2022248858A1 GB 2022051328 W GB2022051328 W GB 2022051328W WO 2022248858 A1 WO2022248858 A1 WO 2022248858A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pathogen
- sodium
- aqueous formulation
- concentration
- alkyl
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 55
- 238000009472 formulation Methods 0.000 title claims description 43
- 244000052769 pathogen Species 0.000 claims abstract description 160
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 149
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 146
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 146
- 239000002157 polynucleotide Substances 0.000 claims abstract description 146
- 239000003945 anionic surfactant Substances 0.000 claims abstract description 95
- 239000013011 aqueous formulation Substances 0.000 claims abstract description 81
- 239000000872 buffer Substances 0.000 claims abstract description 79
- 239000003381 stabilizer Substances 0.000 claims abstract description 65
- 238000000034 method Methods 0.000 claims abstract description 62
- 239000008247 solid mixture Substances 0.000 claims abstract description 46
- 230000002779 inactivation Effects 0.000 claims abstract description 33
- 241000700605 Viruses Species 0.000 claims abstract description 23
- 230000000415 inactivating effect Effects 0.000 claims abstract description 17
- -1 alkyl ether sulfates Chemical class 0.000 claims description 76
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 47
- 239000000523 sample Substances 0.000 claims description 43
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 36
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 36
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical group [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 30
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical group O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 24
- 239000001509 sodium citrate Substances 0.000 claims description 23
- 239000004310 lactic acid Substances 0.000 claims description 18
- 235000014655 lactic acid Nutrition 0.000 claims description 18
- 239000007864 aqueous solution Substances 0.000 claims description 17
- 241001678559 COVID-19 virus Species 0.000 claims description 16
- 150000008051 alkyl sulfates Chemical group 0.000 claims description 15
- 229940001447 lactate Drugs 0.000 claims description 14
- 238000004321 preservation Methods 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 241000894006 Bacteria Species 0.000 claims description 13
- 229910052708 sodium Inorganic materials 0.000 claims description 13
- 239000011734 sodium Substances 0.000 claims description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 12
- 238000001514 detection method Methods 0.000 claims description 12
- 231100001261 hazardous Toxicity 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 12
- 150000008052 alkyl sulfonates Chemical class 0.000 claims description 11
- 229910019142 PO4 Inorganic materials 0.000 claims description 10
- 235000021317 phosphate Nutrition 0.000 claims description 10
- 239000012488 sample solution Substances 0.000 claims description 10
- 241000711573 Coronaviridae Species 0.000 claims description 9
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical group C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000001540 sodium lactate Substances 0.000 claims description 8
- 229940005581 sodium lactate Drugs 0.000 claims description 8
- 235000011088 sodium lactate Nutrition 0.000 claims description 8
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 239000004711 α-olefin Substances 0.000 claims description 6
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 claims description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 5
- 241000725619 Dengue virus Species 0.000 claims description 5
- 241001115402 Ebolavirus Species 0.000 claims description 5
- 241000709661 Enterovirus Species 0.000 claims description 5
- 241000186359 Mycobacterium Species 0.000 claims description 5
- 241001263478 Norovirus Species 0.000 claims description 5
- 241001631646 Papillomaviridae Species 0.000 claims description 5
- 241000991583 Parechovirus Species 0.000 claims description 5
- 241000711798 Rabies lyssavirus Species 0.000 claims description 5
- 241000702670 Rotavirus Species 0.000 claims description 5
- 241000710799 Rubella virus Species 0.000 claims description 5
- 241000315672 SARS coronavirus Species 0.000 claims description 5
- 241000607142 Salmonella Species 0.000 claims description 5
- 241000194017 Streptococcus Species 0.000 claims description 5
- 241000710886 West Nile virus Species 0.000 claims description 5
- 241000907316 Zika virus Species 0.000 claims description 5
- 208000006454 hepatitis Diseases 0.000 claims description 5
- 231100000283 hepatitis Toxicity 0.000 claims description 5
- 241001529453 unidentified herpesvirus Species 0.000 claims description 5
- 241000589876 Campylobacter Species 0.000 claims description 4
- 241000588722 Escherichia Species 0.000 claims description 4
- 241000589601 Francisella Species 0.000 claims description 4
- 241000711467 Human coronavirus 229E Species 0.000 claims description 4
- 241001428935 Human coronavirus OC43 Species 0.000 claims description 4
- 241000204031 Mycoplasma Species 0.000 claims description 4
- 241000588653 Neisseria Species 0.000 claims description 4
- 241000607768 Shigella Species 0.000 claims description 4
- 241000191940 Staphylococcus Species 0.000 claims description 4
- 244000309711 non-enveloped viruses Species 0.000 claims description 4
- 241000607534 Aeromonas Species 0.000 claims description 3
- 241000589562 Brucella Species 0.000 claims description 3
- 241001453380 Burkholderia Species 0.000 claims description 3
- 241000588923 Citrobacter Species 0.000 claims description 3
- 241000193403 Clostridium Species 0.000 claims description 3
- 241000588914 Enterobacter Species 0.000 claims description 3
- 241000194033 Enterococcus Species 0.000 claims description 3
- 241000606790 Haemophilus Species 0.000 claims description 3
- 241001109669 Human coronavirus HKU1 Species 0.000 claims description 3
- 241000482741 Human coronavirus NL63 Species 0.000 claims description 3
- 241000588748 Klebsiella Species 0.000 claims description 3
- 241000588621 Moraxella Species 0.000 claims description 3
- 241000588771 Morganella <proteobacterium> Species 0.000 claims description 3
- 241000606860 Pasteurella Species 0.000 claims description 3
- 241000588769 Proteus <enterobacteria> Species 0.000 claims description 3
- 241000589516 Pseudomonas Species 0.000 claims description 3
- 241000607720 Serratia Species 0.000 claims description 3
- 241000122971 Stenotrophomonas Species 0.000 claims description 3
- 241000607734 Yersinia <bacteria> Species 0.000 claims description 3
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 claims description 3
- BTBJBAZGXNKLQC-UHFFFAOYSA-N ammonium lauryl sulfate Chemical compound [NH4+].CCCCCCCCCCCCOS([O-])(=O)=O BTBJBAZGXNKLQC-UHFFFAOYSA-N 0.000 claims description 3
- 229940063953 ammonium lauryl sulfate Drugs 0.000 claims description 3
- BOUCRWJEKAGKKG-UHFFFAOYSA-N n-[3-(diethylaminomethyl)-4-hydroxyphenyl]acetamide Chemical compound CCN(CC)CC1=CC(NC(C)=O)=CC=C1O BOUCRWJEKAGKKG-UHFFFAOYSA-N 0.000 claims description 3
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 3
- 150000003871 sulfonates Chemical class 0.000 claims description 3
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 claims description 2
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 2
- 241000606161 Chlamydia Species 0.000 claims description 2
- 241000605909 Fusobacterium Species 0.000 claims description 2
- 241000589989 Helicobacter Species 0.000 claims description 2
- 241000589248 Legionella Species 0.000 claims description 2
- 208000007764 Legionnaires' Disease Diseases 0.000 claims description 2
- 241000186781 Listeria Species 0.000 claims description 2
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims description 2
- 125000005599 alkyl carboxylate group Chemical group 0.000 claims description 2
- 150000007942 carboxylates Chemical class 0.000 claims description 2
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 claims description 2
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 claims description 2
- 150000003893 lactate salts Chemical group 0.000 claims description 2
- QHVJMQSXCDOHMT-UHFFFAOYSA-M sodium 2-butyloctyl sulfate Chemical compound [Na+].CCCCCCC(CCCC)COS([O-])(=O)=O QHVJMQSXCDOHMT-UHFFFAOYSA-M 0.000 claims description 2
- WBTKKIYZNGGPNA-UHFFFAOYSA-M sodium 3,7-dimethyloctyl sulfate Chemical compound [Na+].CC(C)CCCC(C)CCOS([O-])(=O)=O WBTKKIYZNGGPNA-UHFFFAOYSA-M 0.000 claims description 2
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 claims description 2
- 229940057950 sodium laureth sulfate Drugs 0.000 claims description 2
- 229940079862 sodium lauryl sarcosinate Drugs 0.000 claims description 2
- MDSQKJDNWUMBQQ-UHFFFAOYSA-M sodium myreth sulfate Chemical compound [Na+].CCCCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O MDSQKJDNWUMBQQ-UHFFFAOYSA-M 0.000 claims description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 claims description 2
- 229940067741 sodium octyl sulfate Drugs 0.000 claims description 2
- SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 claims description 2
- ADWNFGORSPBALY-UHFFFAOYSA-M sodium;2-[dodecyl(methyl)amino]acetate Chemical compound [Na+].CCCCCCCCCCCCN(C)CC([O-])=O ADWNFGORSPBALY-UHFFFAOYSA-M 0.000 claims description 2
- DGSDBJMBHCQYGN-UHFFFAOYSA-M sodium;2-ethylhexyl sulfate Chemical compound [Na+].CCCCC(CC)COS([O-])(=O)=O DGSDBJMBHCQYGN-UHFFFAOYSA-M 0.000 claims description 2
- XQCHMGAOAWZUPI-UHFFFAOYSA-M sodium;butane-1-sulfonate Chemical compound [Na+].CCCCS([O-])(=O)=O XQCHMGAOAWZUPI-UHFFFAOYSA-M 0.000 claims description 2
- AIMUHNZKNFEZSN-UHFFFAOYSA-M sodium;decane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCS([O-])(=O)=O AIMUHNZKNFEZSN-UHFFFAOYSA-M 0.000 claims description 2
- REFMEZARFCPESH-UHFFFAOYSA-M sodium;heptane-1-sulfonate Chemical compound [Na+].CCCCCCCS([O-])(=O)=O REFMEZARFCPESH-UHFFFAOYSA-M 0.000 claims description 2
- QWSZRRAAFHGKCH-UHFFFAOYSA-M sodium;hexane-1-sulfonate Chemical compound [Na+].CCCCCCS([O-])(=O)=O QWSZRRAAFHGKCH-UHFFFAOYSA-M 0.000 claims description 2
- RUYRDULZOKULPK-UHFFFAOYSA-M sodium;nonane-1-sulfonate Chemical compound [Na+].CCCCCCCCCS([O-])(=O)=O RUYRDULZOKULPK-UHFFFAOYSA-M 0.000 claims description 2
- HRQDCDQDOPSGBR-UHFFFAOYSA-M sodium;octane-1-sulfonate Chemical compound [Na+].CCCCCCCCS([O-])(=O)=O HRQDCDQDOPSGBR-UHFFFAOYSA-M 0.000 claims description 2
- WFRKJMRGXGWHBM-UHFFFAOYSA-M sodium;octyl sulfate Chemical compound [Na+].CCCCCCCCOS([O-])(=O)=O WFRKJMRGXGWHBM-UHFFFAOYSA-M 0.000 claims description 2
- ROBLTDOHDSGGDT-UHFFFAOYSA-M sodium;pentane-1-sulfonate Chemical compound [Na+].CCCCCS([O-])(=O)=O ROBLTDOHDSGGDT-UHFFFAOYSA-M 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims 1
- 229920002477 rna polymer Polymers 0.000 description 45
- 229910052783 alkali metal Inorganic materials 0.000 description 32
- 108020004414 DNA Proteins 0.000 description 27
- 102000053602 DNA Human genes 0.000 description 27
- 239000000126 substance Substances 0.000 description 17
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- 241000894007 species Species 0.000 description 12
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 9
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 9
- 150000001340 alkali metals Chemical class 0.000 description 9
- 229910052744 lithium Inorganic materials 0.000 description 9
- 229910052700 potassium Inorganic materials 0.000 description 9
- 239000011591 potassium Substances 0.000 description 9
- 238000005070 sampling Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 241000233866 Fungi Species 0.000 description 6
- 108010052285 Membrane Proteins Proteins 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 108020004635 Complementary DNA Proteins 0.000 description 5
- 238000010804 cDNA synthesis Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 239000003599 detergent Substances 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- FTEDXVNDVHYDQW-UHFFFAOYSA-N BAPTA Chemical compound OC(=O)CN(CC(O)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(O)=O)CC(O)=O FTEDXVNDVHYDQW-UHFFFAOYSA-N 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 229910052792 caesium Inorganic materials 0.000 description 4
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 229950007919 egtazic acid Drugs 0.000 description 4
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000004779 membrane envelope Anatomy 0.000 description 4
- 239000000693 micelle Substances 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 229910052701 rubidium Inorganic materials 0.000 description 4
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 208000025721 COVID-19 Diseases 0.000 description 3
- 206010015946 Eye irritation Diseases 0.000 description 3
- 101710172711 Structural protein Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 231100000013 eye irritation Toxicity 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 3
- 231100000330 serious eye damage Toxicity 0.000 description 3
- 239000006163 transport media Substances 0.000 description 3
- 238000012211 viral plaque assay Methods 0.000 description 3
- BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 description 2
- 241000228212 Aspergillus Species 0.000 description 2
- 241000193738 Bacillus anthracis Species 0.000 description 2
- 241000335423 Blastomyces Species 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 241000606153 Chlamydia trachomatis Species 0.000 description 2
- 241000223203 Coccidioides Species 0.000 description 2
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 241000605952 Fusobacterium necrophorum Species 0.000 description 2
- 241000224467 Giardia intestinalis Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101710114810 Glycoprotein Proteins 0.000 description 2
- 206010018612 Gonorrhoea Diseases 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 241000228402 Histoplasma Species 0.000 description 2
- 241000589242 Legionella pneumophila Species 0.000 description 2
- 241000186779 Listeria monocytogenes Species 0.000 description 2
- 241001480037 Microsporum Species 0.000 description 2
- 241000235395 Mucor Species 0.000 description 2
- 241000588650 Neisseria meningitidis Species 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 241001537205 Paracoccidioides Species 0.000 description 2
- 201000005702 Pertussis Diseases 0.000 description 2
- 101710167605 Spike glycoprotein Proteins 0.000 description 2
- 241001149962 Sporothrix Species 0.000 description 2
- 241000193985 Streptococcus agalactiae Species 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 238000011053 TCID50 method Methods 0.000 description 2
- 241000228341 Talaromyces Species 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 241000589884 Treponema pallidum Species 0.000 description 2
- 241000223238 Trichophyton Species 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 229940065181 bacillus anthracis Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 150000007516 brønsted-lowry acids Chemical class 0.000 description 2
- 150000007528 brønsted-lowry bases Chemical class 0.000 description 2
- 229940038705 chlamydia trachomatis Drugs 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229940115932 legionella pneumophila Drugs 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 239000005725 8-Hydroxyquinoline Substances 0.000 description 1
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 241001504639 Alcedo atthis Species 0.000 description 1
- 125000006539 C12 alkyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 241000223935 Cryptosporidium Species 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000250507 Gigaspora candida Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 101150001779 ORF1a gene Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 101150010882 S gene Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 241000224527 Trichomonas vaginalis Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 231100001010 corrosive Toxicity 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000007799 dermal corrosion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940071161 dodecylbenzenesulfonate Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 244000309457 enveloped RNA virus Species 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052730 francium Inorganic materials 0.000 description 1
- KLMCZVJOEAUDNE-UHFFFAOYSA-N francium atom Chemical compound [Fr] KLMCZVJOEAUDNE-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000000937 inactivator Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000002687 intercalation Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 229940071204 lauryl sarcosinate Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229940067739 octyl sulfate Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229960003540 oxyquinoline Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000003330 peritoneal dialysis fluid Substances 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000006432 protein unfolding Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100000108 skin corrosion Toxicity 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical group [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- NGSFWBMYFKHRBD-DKWTVANSSA-M sodium;(2s)-2-hydroxypropanoate Chemical compound [Na+].C[C@H](O)C([O-])=O NGSFWBMYFKHRBD-DKWTVANSSA-M 0.000 description 1
- XZTJQQLJJCXOLP-UHFFFAOYSA-M sodium;decyl sulfate Chemical compound [Na+].CCCCCCCCCCOS([O-])(=O)=O XZTJQQLJJCXOLP-UHFFFAOYSA-M 0.000 description 1
- WSVLUYNDHYCZGD-UHFFFAOYSA-M sodium;hexyl sulfate Chemical compound [Na+].CCCCCCOS([O-])(=O)=O WSVLUYNDHYCZGD-UHFFFAOYSA-M 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- CSMFSDCPJHNZRY-UHFFFAOYSA-N sulfuric acid monodecyl ester Natural products CCCCCCCCCCOS(O)(=O)=O CSMFSDCPJHNZRY-UHFFFAOYSA-N 0.000 description 1
- UZZYXUGECOQHPU-UHFFFAOYSA-N sulfuric acid monooctyl ester Natural products CCCCCCCCOS(O)(=O)=O UZZYXUGECOQHPU-UHFFFAOYSA-N 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000008478 viral entry into host cell Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N41/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom
- A01N41/02—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom containing a sulfur-to-oxygen double bond
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/30—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/06—Lysis of microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20061—Methods of inactivation or attenuation
- C12N2770/20063—Methods of inactivation or attenuation by chemical treatment
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- This invention relates to a formulation for inactivating a pathogen, and more particularly to a formulation comprising an anionic surfactant, a buffer and a polynucleotide stabiliser.
- the invention also relates to a method of inactivating a pathogen.
- BACKGROUND [0002] Infectious disease testing is an important tool in modern medicine. Interest in this field has grown substantially following the emergence of coronavirus disease 2019 (COVID-19) as a global pandemic.
- samples in the laboratory without inactivation, samples in the laboratory, especially those containing respiratory or high-containment pathogens, need to be handled inside a safety cabinet, limiting workspace and throughput. It is also important that the sample collection and inactivation method avoid (or at least minimise) degradation of the nucleic acid material, to ensure efficient molecular detection.
- sample collection and inactivation method avoid (or at least minimise) degradation of the nucleic acid material, to ensure efficient molecular detection.
- heat-inactivation and chemical inactivation see, e.g., “Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products”, WHO Technical Report, Series No.924, 2004, Annex 4; E.
- an aqueous formulation for inactivating a pathogen comprising: an anionic surfactant in a concentration of from about 15 mM to about 70 mM; a polynucleotide stabiliser in a concentration of from about 1 mM to about 200 mM; and a buffer providing a pH of from about 2 to about 4.2.
- a second aspect of the invention provides a use of an aqueous formulation of the first aspect for the inactivation of a pathogen, optionally wherein the use further comprises the preservation of pathogen polynucleotides.
- a third aspect of the invention provides a use of an aqueous formulation of the first aspect for the preservation of pathogen polynucleotides.
- the polynucleotide may be RNA or DNA.
- the polynucleotide may be RNA.
- the polynucleotide may be DNA.
- a fourth aspect of the invention provides a method of inactivating a pathogen, the method comprising contacting a sample containing the pathogen with a formulation of the first aspect.
- a fifth aspect of the invention comprises a method of preserving pathogen polynucleotides, the method comprising contacting a sample containing the pathogen with a formulation of the first aspect to provide a contacted sample, and optionally storing the contacted sample.
- a sixth aspect of the invention provides a solid mixture comprising: an anionic surfactant in an amount of from about 50% to about 70% by weight; a buffer in an amount of from about 20% to about 30% by weight; and a polynucleotide stabiliser in an amount of from about 2% to about 20% by weight.
- a seventh aspect of the invention provides a use of a solid mixture of the sixth aspect for the inactivation of a pathogen. The use comprises contacting an aqueous sample containing the pathogen with the solid mixture. The use may further comprise the preservation of pathogen polynucleotides.
- An eighth aspect of the invention provides a use of solid mixture of the sixth aspect for the preservation of pathogen polynucleotides.
- a ninth aspect of the invention provides a method of inactivating a pathogen, the method comprising contacting an aqueous sample containing the pathogen with a solid mixture of the sixth aspect.
- a tenth aspect of the invention comprises a method of preserving pathogen polynucleotides, the method comprising contacting an aqueous sample containing the pathogen with a solid mixture of the sixth aspect to provide a contacted sample, and optionally storing the contacted sample.
- An eleventh aspect of the invention provides a method of identifying a pathogen, comprising: contacting a sample containing a suspected pathogen with an aqueous formulation of the first aspect to provide a sample solution comprising suspected pathogen polynucleotides; storing and/or transporting the sample solution; separating the suspected pathogen polynucleotides from the solution; subjecting the suspected pathogen polynucleotides to a detection process, and identifying said suspected pathogen, if present, based on the detected pathogen polynucleotides.
- a twelfth aspect of the invention provides a method of identifying a pathogen, comprising: contacting an aqueous sample containing a suspected pathogen with a solid mixture of the fifth aspect to provide a sample solution comprising suspected pathogen polynucleotides; storing and/or transporting the sample solution; separating the suspected pathogen polynucleotides from the solution; subjecting the suspected pathogen polynucleotides to a detection process, and identifying said suspected pathogen, if present, based on the detected pathogen polynucleotides.
- a thirteenth aspect of the invention provides a kit comprising: a container comprising an aqueous formulation of the first aspect or a solid mixture of the sixth aspect; and optionally a sterile swab and/or funnel.
- a container comprising an aqueous formulation of the first aspect or a solid mixture of the sixth aspect; and optionally a sterile swab and/or funnel.
- Figure 2 shows the interaction of detergent sodium dodecyl sulfate (SDS) with lipid envelopes: (a) illustrates a membrane structure in the absence SDS; (b) illustrates intercalation of detergent monomers into the membrane structure; and (c) illustrates the situation when detergent monomers have solubilised the membrane proteins.
- SDS detergent sodium dodecyl sulfate
- alkali metal refers to an element from Group 1 of the periodic table, i.e. lithium, sodium, potassium, rubidium, caesium, and francium.
- Compounds of the disclosure that comprise an alkali metal may comprise lithium, sodium, potassium, rubidium, or caesium.
- such a compound may comprise lithium, sodium, or potassium; e.g. the compound may comprise sodium.
- buffer in the present disclosure refers to a conjugate pair comprising of a Br ⁇ nsted-Lowry acid (HA) and its conjugate Br ⁇ nsted-Lowry base (A ' ).
- HA Br ⁇ nsted-Lowry acid
- a ' Br ⁇ nsted-Lowry base
- the buffers of the present invention are acidic buffers comprising an acid and a salt. In these acidic buffers, molecules HA and ions A ' are present. When acid is added, the additional protons are removed by the ions A ' . When base is added, the additional hydroxide ions are removed by reaction with undissociated acid HA:
- % w/v refers to the percentage weight of a particular component per unit volume of solution: [0031] The term “% by weight” refers to the percentage weight of a particular component per unit weight. For example, the % by weight of a solid represents the percentage of the weight that the component is of the total amount of solid. [0032] The concentration (i.e.
- inactivation of or “inactivating” a pathogen refers to a process of enhancing safety in which the pathogen is intentionally “killed”.
- the level of inactivation is typically expressed using log reduction factor (LRF), which refers to a quantity of pathogen, expressed on a log 10 scale that is inactivated.
- LRF log reduction factor
- an LRF of 4 comprises a 10,000 reduction factor, corresponding to inactivation of 99.99% of the pathogen.
- Inactivation may comprise > 4 LRF, e.g. inactivation may comprise > 5 LRF.
- LRF may be measured using a suitable method for the pathogen, for example, using a viral plaque assay, a bacterial plaque assay, or TCID 50 assay (where TCID 50 is defined as the amount of pathogen that causes the death of 50% of cells).
- TCID 50 is defined as the amount of pathogen that causes the death of 50% of cells.
- Exemplary viral plaque assay protocols for determining the LRF are described in E. J. Mendoza et al. (Curr. Protoc. Microbiol., 2020, 57, 1) and N. Bracci et al. (PeerJ, 2020, 8, 10639).
- Exemplary TCID 50 assay protocols for determining the LRF are described in C. M. Coleman et al. (Curr. Protoc.
- hazardous refers to a substance, mixture of substances, or a process involving substances that, under production, usage, or disposal conditions, make it capable of causing adverse effects to non-pathogenic organisms, depending on the degree of exposure. Whether a substance or mixture of substances are hazardous may be dependent on concentration.
- nucleic acid molecule(s) or “polynucleotide(s)” refers to any compound(s) and/or substance(s) that comprise a polymer of nucleotides.
- Each nucleotide is composed of a base, specifically a purine- or pyrimidine base (i.e., cytosine (C), guanine (G), adenine (A), thymine (T) or uracil (U)), a sugar (i.e., deoxyribose or ribose), and a phosphate group.
- nucleic acid molecule is described by the sequence of bases, whereby said bases represent the primary structure (linear structure) of a nucleic acid molecule.
- the sequence of bases is typically represented from 5’ to 3’.
- nucleic acid molecule encompasses deoxyribonucleic acid (DNA) including, e.g., complementary DNA (cDNA) and genomic DNA, ribonucleic acid (RNA), e.g. messenger RNA (mRNA), synthetic forms of DNA or RNA, and mixed polymers comprising two or more of these molecules.
- DNA deoxyribonucleic acid
- RNA e.g. messenger RNA (mRNA)
- mRNA messenger RNA
- the nucleic acid molecule can be linear or circular.
- nucleic acid molecule includes both, sense and antisense strands, as well as single stranded and double stranded forms.
- the herein described nucleic acid molecule can contain naturally occurring or non-naturally occurring nucleotides. Examples of non-naturally occurring nucleotides include modified nucleotide bases with derivatized sugars or phosphate backbone linkages or chemically modified residues.
- pathogen refers to any organism which causes a disease. The organism may be a virus, bacterium, fungus, or a parasite.
- the pathogen may be a virus, for example a coronavirus, a rotavirus, a norovirus, an enterovirus, a hepatitis virus, a herpes virus, a papilloma virus, an arbovirus (e.g. West Nile virus, Zika virus, Dengue virus), an ebolavirus, an orthomyxovirus, a paramyxovirus, a rabies virus, a parecho virus, or a rubella virus.
- a virus for example a coronavirus, a rotavirus, a norovirus, an enterovirus, a hepatitis virus, a herpes virus, a papilloma virus, an arbovirus (e.g. West Nile virus, Zika virus, Dengue virus), an ebolavirus, an orthomyxovirus, a paramyxovirus, a rabies virus, a parecho virus, or a rubella virus.
- the pathogen may be a bacterium, for example a Clostridium, a Pseudomonas, an Escherichia, a Klebsiella, an Enterococcus, an Enterobacter, a Serratia, a Stenotrophomonas, an Aeromonas, a Morganella, a Yersinia, a Salmonella, a Proteus, a Pasteurella, a Haemophilus, a Citrobacter, a Burkholderia, a Brucella, a Moraxella, a Mycobacterium, a Streptococcus or a Staphylococcus.
- a bacterium for example a Clostridium, a Pseudomonas, an Escherichia, a Klebsiella, an Enterococcus, an Enterobacter, a Serratia, a Stenotrophomonas, an Aeromonas, a Morganella
- the pathogen may be a fungus, for example a Candida, a Blastomyces, a Coccidioides, a Paracoccidioides, a Histoplasma, a Cryptococcus, a Trichophyton, a Microsporum, a Mucor, an Aspergillus, a Sporothrix, or a Talaromyces.
- the term “polynucleotide stabiliser” refers to a substance that stabilises and protects cellular and/or pathogen RNA or DNA in solution, in particular substances that chelate metal ions and prevent oxidative activity of nuclease enzymes.
- Exemplary polynucleotide stabilisers include citrates, ethylenediaminetetraacetic acid (EDTA), ethylene glycol-bis( ⁇ -aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA), 1,2- cyclohexylenedinitrilo)tetraacetic acid (CDTA), 1,2-bis(o-aminophenoxy)ethane-N,N,N′,N′- tetraacetic acid (BAPTA), 8-hydroxyquinoline, citric acid, tartaric acid, lithium chloride, sodium chloride, and magnesium chloride.
- EDTA ethylenediaminetetraacetic acid
- EGTA ethylene glycol-bis( ⁇ -aminoethyl ether)-N,N,N′,N′-tetraacetic acid
- CDTA 1,2- cyclohexylenedinitrilo)tetraacetic acid
- BAPTA 1,2-bis(
- exemplary anionic surfactants comprise an alkali metal cation, such as sodium. While such compounds may be disclosed with a given alkali metal cation, as the skilled person will appreciate, in aqueous solution the identity of the alkali metal cation does not affect the behaviour of the anion. Thus in such compounds disclosed herein, sodium may be substituted with lithium, potassium, rubidium, or caesium. For example, sodium may be replaced with lithium or potassium.
- disclosure of a compound with any one specific alkali metal cation also includes disclosure of the corresponding compound with each other specific alkali metal cation (such as lithium, potassium, rubidium, or caesium; e.g. lithium or potassium).
- FORMULATIONS [0039] In any of the following paragraphs, the term “comprising” may be replaced with the terms “substantially consisting of” or “consisting of” as appropriate. [0040] Formulations of the invention are suitable for the inactivation of pathogens.
- the formulations described herein comprise (or substantially consist of, or consists of): an anionic surfactant in a concentration of from about 15 mM to about 70 mM; a polynucleotide stabiliser in a concentration of from about 1 mM to about 200 mM; and a buffer providing a pH of from about 2 to about 4.2.
- the anionic surfactant may be present in a concentration of at least about 15 mM, at least about 20 mM, at least about 22 mM, or at least about 26 mM.
- the anionic surfactant may be present in a concentration of no more than about 70 mM, no more than about 60 mM, no more than about 50 mM, no more than about 40 mM, no more than about 35 mM, no more than about 30 mM, no more than about 28 mM, or no more than about 26 mM.
- the anionic surfactant may be present in a concentration of from about 15 mM to about 70 mM.
- the anionic surfactant may be present in a concentration of from about 15 mM to about 50 mM.
- the anionic surfactant may be present in a concentration of from about 15 mM to about 35 mM.
- the anionic surfactant may be present in a concentration of from about 15 mM to about 30 mM.
- the anionic surfactant may be present in a concentration of from about 15 mM to about 28 mM.
- the anionic surfactant may be present in a concentration of from about 15 mM to about 26 mM.
- the anionic surfactant may be present in a concentration of from about 20 mM to about 70 mM.
- the anionic surfactant may be present in a concentration of from about 20 mM to about 50 mM.
- the anionic surfactant may be present in a concentration of from about 20 mM to about 35 mM.
- the anionic surfactant may be present in a concentration of from about 20 mM to about 30 mM.
- the anionic surfactant may be present in a concentration of from about 20 mM to about 28 mM.
- the anionic surfactant may be present in a concentration of from about 20 mM to about 26 mM.
- the anionic surfactant may be present in a concentration of from about 22 mM to about 35 mM.
- the anionic surfactant may be present in a concentration of from about 22 mM to about 30 mM.
- the anionic surfactant may be present in a concentration of from about 22 mM to about 28 mM.
- the anionic surfactant may be present in a concentration of from about 24 mM to about 28 mM.
- the anionic surfactant may be present in a concentration of from about 22 mM to about 26 mM.
- the anionic surfactant may be present in a concentration of from about 26 mM to about 35 mM.
- the anionic surfactant may be present in a concentration of from about 26 mM to about 30 mM.
- the anionic surfactant may be present in a concentration of from about 26 mM to about 28 mM.
- the anionic surfactant may present in a concentration of about 26 mM.
- the anionic surfactant may comprise a species selected from: alkyl sulfates, alkyl ether sulfates, arylalkyl sulfates, alkyl aryl ether sulfates alkyl ester sulfates, alkyl sulfonates, alkyl ether sulfonates, arylalkyl sulfonates, alkyl aryl ether sulfonates, alkyl ester sulfonates, alkyl ⁇ -olefin sulfonates, alkyl phosphates, alkyl ether phosphates, arylalkyl phosphates, alkyl aryl ether phosphates, alkyl ester phosphates, alkyl carboxylates, alkylamido carboxylates, alkyl ether carboxylates, arylalkyl carboxylates, alkyl aryl ether carboxylate
- the anionic surfactant may comprise a species selected from: alkyl sulfates, alkyl ether sulfates, alkyl aryl ether sulfates alkyl ester sulfates, alkyl sulfonates, alkyl ether sulfonates, alkyl aryl ether sulfonates, alkyl ester sulfonates, alkyl ⁇ -olefin sulfonates.
- the anionic surfactant may comprise a species selected from: alkyl sulfates, alkyl ether sulfates, alkyl aryl ether sulfates, alkyl ester sulfates.
- the anionic surfactant may comprise a species selected from: alkyl sulfates, alkyl ether sulfates.
- the anionic surfactant may comprise an alkyl sulfate species.
- the anionic surfactant may comprise an alkyl ether sulfate species.
- the anionic surfactant may comprise an alkyl sulfonate species.
- the anionic surfactant may comprise a C 4-24 alkyl sulfate, a C 4-24 alkyl sulfonate or a C 4-24 alkyl ether sulfate.
- the anionic surfactant may comprise a C 6-24 alkyl sulfate, a C 6-24 alkyl sulfonate or a C 6-24 alkyl ether sulfate.
- the anionic surfactant may comprise a C 8-24 alkyl sulfate, a C 8-24 alkyl sulfonate or a C 8-24 alkyl ether sulfate.
- the anionic surfactant may comprise a C 8-18 alkyl sulfate, a C 8-18 alkyl sulfonate or a C 8-18 alkyl ether sulfate.
- the anionic surfactant may comprise a C 10-18 alkyl sulfate, a C 10-18 alkyl sulfonate or a C 10-18 alkyl ether sulfate.
- the anionic surfactant may comprise a C 10-14 alkyl sulfate, C 10-14 alkyl sulfonate or C 10-14 alkyl ether sulfate.
- the anionic surfactant may comprise a C 10-14 alkyl sulfate.
- the anionic surfactant may comprise a C 10-14 alkyl sulfonate.
- the anionic surfactant may comprise a C10-14 alkyl ether sulfate.
- the anionic surfactant may comprise a C12 alkyl sulfate.
- the anionic surfactant may comprise or may be selected from: alkali metal dodecyl sulfate, alkali metal decyl sulfate, alkali metal octyl sulfate, alkali metal hexyl sulfate, alkali metal butyl sulfate, alkali metal 2-butyloctyl sulfate, alkali metal 2-ethylhexyl sulfate, alkali metal 3,7-dimethyloctyl sulfate, alkali metal lauryl sulfate, alkali metal lauryl sarcosinate, ammonium lauryl sulfate, alkali metal laureth sulfate, ammonium laureth sulfate, alkali metal myreth sulfate, alkali metal pareth sulfate, C14-16 alkyl ⁇ -olefin sulfon
- the anionic surfactant may comprise or may be selected from: sodium dodecyl sulfate, sodium decyl sulfate, sodium octyl sulfate, sodium hexyl sulfate, sodium 2-butyloctyl sulfate, sodium 2-ethylhexyl sulfate, sodium 3,7- dimethyloctyl sulfate, sodium lauryl sulfate, sodium lauryl sarcosinate, ammonium lauryl sulfate, sodium laureth sulfate, ammonium laureth sulfate, sodium myreth sulfate, sodium pareth sulfate, C14-16 alkyl ⁇ -olefin sulfonate, sodium dodecylbenzene sulfonate, sodium octanesulfonate, sodium decanesulfonate, sodium nonanesulfonate, sodium hept
- the anionic surfactant comprises or is sodium dodecyl sulfate.
- the anionic surfactant may be selected from any of the anionic surfactant species identified in WO 2006/062835A2 (in particular the anionic surfactant species identified in WO 2006/062835A2 from page 25, line 24 to page 27, line 18), the contents of which are incorporated herein by reference.
- sodium dodecyl sulfate in an amount of about 35 mM ( ⁇ 1% w/v) and higher is considered to be hazardous to the user.
- sodium dodecyl sulfate is considered a Category 1 hazard for serious eye damage/eye irritation, which according to Table 3.3.3 on page 138 of REGULATION (EC) No 1272/2008 (the content of which is incorporated herein by reference) may be hazardous at a concentration of greater than 1%.
- the anionic surfactant may comprise (or substantially consist of, or consist of) sodium dodecyl sulfate in a concentration of no more than about 35 mM.
- the anionic surfactant may comprise sodium dodecyl sulfate in a concentration of from about 15 mM to about 35 mM.
- the anionic surfactant may comprise sodium dodecyl sulfate in a concentration of from about 20 mM to about 30 mM.
- the anionic surfactant may comprise sodium dodecyl sulfate in a concentration of from about 22 mM to about 28 mM.
- the anionic surfactant may comprise sodium dodecyl sulfate in a concentration of about 26 mM.
- the anionic surfactant may be sodium dodecyl sulfate in an amount of no more than about 1% w/v.
- the anionic surfactant may be sodium dodecyl sulfate in an amount of from about 0.5% to about 1% w/v, e.g.
- the anionic may be sodium dodecyl sulfate in an amount of from greater than 0.5% to less than 1% w/v, e.g. from greater than 0.6% to less than 1% w/v, from greater than 0.7% to less than 1% w/v, from greater than 0.8% to less than 1% w/v, from greater than 0.9% to less than 1% w/v.
- the anionic surfactant may be sodium dodecyl sulfate in an amount of from about 0.5% to about 0.95% w/v, from about 0.5% to about 0.9% w/v, from about 0.5% to about 0.85% w/v, from about 0.5% to about 0.8% w/v, or from about 0.5% to about 0.75% w/v.
- the anionic surfactant may be sodium dodecyl sulfate in an amount of from about 0.6% to about 0.95% w/v, from about 0.6% to about 0.9% w/v, from about 0.6% to about 0.85% w/v, from about 0.6% to about 0.8% w/v, or from about 0.6% to about 0.75% w/v.
- the anionic surfactant may be sodium dodecyl sulfate in an amount of from about 0.7% to about 0.95% w/v, from about 0.7% to about 0.9% w/v, from about 0.7% to about 0.85% w/v, from about 0.7% to about 0.8% w/v, or from about 0.7% to about 0.75% w/v.
- the anionic surfactant may be sodium dodecyl sulfate in an amount of about 0.75% w/v.
- the aqueous formulation may have a pH of about from about 3 to about 4.2.
- the aqueous formulation may have a pH of from about 3 to about 4.
- the aqueous formulation may have a pH of from about 3.2 to about 3.8.
- the aqueous formulation may have a pH of from about 3.2 to about 3.6.
- the aqueous formulation may have a pH of from about 3.4 to about 3.8.
- the aqueous formulation may have a pH of from about 3.4 to about 3.6.
- the aqueous formulation may have a pH of about 3.5.
- the aqueous formulation may have a pH of at least about 3, about 3.1, about 3.2, about 3.3, about 3.4, or about 3.5.
- the aqueous formulation may have a pH of at least about 3.4 or about 3.5; e.g. the aqueous formulation may have a pH of at least about 3.5.
- the aqueous formulation may have a pH of not more than about 4.2, about 4.1, or about 4.
- the aqueous formulation may have a pH of about from about 3.2 to about 4.2.
- the aqueous formulation may have a pH of about from about 3.5 to about 4.2.
- the anionic surfactant may be sodium dodecyl sulfate and the aqueous formulation may have a pH of from about 3 to about 4.
- the anionic surfactant may be sodium dodecyl sulfate and the aqueous formulation may have a pH of from about 3.2 to about 3.8.
- the anionic surfactant may be sodium dodecyl sulfate and the aqueous formulation may have a pH of from about 3.2 to about 3.6.
- the anionic surfactant may be sodium dodecyl sulfate and the aqueous formulation may have a pH of from about 3.4 to about 3.8.
- the anionic surfactant may be sodium dodecyl sulfate and the aqueous formulation may have a pH of from about 3.4 to about 3.6.
- the anionic surfactant may be sodium dodecyl sulfate and the aqueous formulation may have a pH of about 3.5.
- the anionic surfactant may be sodium dodecyl sulfate and the aqueous formulation may have a pH of from about 3.2 to about 4.2.
- the anionic surfactant may be sodium dodecyl sulfate and the aqueous formulation may have a pH of from about 3.5 to about 4.2.
- the inventors have surprisingly found that the use of sodium dodecyl sulfate at low pH, e.g. a pH of less than 4.5, has the combined effect of inactivating pathogens while preserving the pathogen polynucleotides. It is believed that a pH of less than 2 will cause degradation of the pathogen nucleotides. Accordingly, the aqueous formulations of the present invention advantageously have pH of from about 2 to about 4.2. Formulations having a pH of about 3.5 may be preferred.
- the buffer may comprise or may be selected from a species having a suitable pKa value to maintain a pH of from about 2 to about 4.2 (e.g. from about 3 to about 4.2, from about 3 to about 4, from about 3.2 to about 3.8, or about 3.5).
- the buffer may comprise or may be selected from: lactate/lactic acid, glycine – hydrochloric acid, acetate/acetic acid and citrate/citric acid.
- the buffer may comprise or may be selected from: lactate/lactic acid and glycine – hydrochloric acid.
- the buffer may comprise or may be lactate/lactic acid.
- the buffer may comprise or may be glycine – hydrochloric acid.
- the lactate, acetate and citrate species of the buffer may comprise lactic acid, acetic acid and citric acid respectively and salts thereof.
- the lactate, acetate and citrate species may comprise alkali metal salts thereof (e.g. lithium, sodium, and/or potassium).
- the buffer is sodium lactate/lactic acid.
- the sodium can be replaced with another alkali metal (e.g. lithium, potassium) as the counter ion where possible.
- the buffer may be in a concentration of from about 1 mM to about 500 mM.
- the buffer may be in a concentration of from about 5 mM to about 150 mM.
- the buffer may be in a concentration of from about 5 mM to about 100 mM.
- the buffer may be in a concentration of from about 5 mM to about 50 mM.
- the buffer may be in a concentration of from about 5 mM to about 25 mM.
- the buffer may be in a concentration of from about 5 mM to about 15 mM.
- the buffer may be in a concentration of from about 5 mM to about 10 mM.
- the buffer may be in a concentration of about 10 mM.
- the buffer may be lactate/lactic acid (e.g. sodium lactate/lactic acid) in a concentration sufficient to maintain a pH of from about 2 to about 4.2 (e.g. from about 3 to about 4.2, from about 3 to about 4, from about 3.2 to about 3.8, or about 3.5).
- the buffer may be lactate/lactic acid (e.g. sodium lactate/lactic acid) in a concentration of from about 5 mM to about 150 mM, from about 5 mM to about 100 mM, from about 5 mM to about 50 mM, from about 5 mM to about 25 mM, from about 5 mM to about 15 mM, or from about 5 mM to about 10 mM.
- the buffer may be lactate/lactic acid (e.g. sodium lactate/lactic acid) in a concentration of about 10 mM.
- the buffer is lactate/lactic acid (e.g. sodium lactate/lactic acid)
- the lactate may be present in an amount of from about 0.03% to about 0.07% w/v (e.g.
- the polynucleotide stabiliser may be in a concentration of from about 1 mM to about 200 mM.
- the polynucleotide stabiliser may be in a concentration of from about 1 mM to about 150 mM.
- the polynucleotide stabiliser may be in a concentration of from about 1 mM to about 100 mM.
- the polynucleotide stabiliser may be in a concentration of from about 1 mM to about 50 mM.
- the polynucleotide stabiliser may be in a concentration of from about 1 mM to about 25 mM.
- the polynucleotide stabiliser may be in a concentration of from about 1 mM to about 20 mM.
- the polynucleotide stabiliser may be in a concentration of from about 1 mM to about 15 mM.
- the polynucleotide stabiliser may be in a concentration of from about 1 mM to about 10 mM.
- the polynucleotide stabiliser may be in a concentration of from about 1 mM to about 9 mM.
- the polynucleotide stabiliser may be in a concentration of from about 1 mM to about 8 mM.
- the polynucleotide stabiliser may be in a concentration of from about 1 mM to about 7 mM.
- the polynucleotide stabiliser may be in a concentration of from about 1 mM to about 6 mM.
- the polynucleotide stabiliser may be in a concentration of from about 1 mM to about 5 mM.
- the polynucleotide stabiliser may be in a concentration of from about 1 mM to about 4 mM.
- the polynucleotide stabiliser may be in a concentration of from about 1 mM to about 3 mM.
- the polynucleotide stabiliser may be in a concentration of from about 1.2 mM to about 2.8 mM.
- the polynucleotide stabiliser may be in a concentration of from about 1.5 mM to about 2.5 mM.
- the polynucleotide stabiliser may be in a concentration of about 2 mM.
- the polynucleotide stabiliser may comprise or be selected from: citrate, ethylenediaminetetraacetic acid (EDTA), ethylene glycol-bis( ⁇ -aminoethyl ether)-N,N,N′,N′- tetraacetic acid (EGTA), 1,2-cyclohexylenedinitrilo)tetraacetic acid (CDTA), 1,2-bis(o- aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid (BAPTA), 8-hydrozyquinoline, citric acid, tartaric acid, lithium chloride, sodium chloride, and magnesium chloride.
- EDTA ethylenediaminetetraacetic acid
- EGTA ethylene glycol-bis( ⁇ -amin
- the polynucleotide stabiliser is citrate (e.g. sodium citrate).
- the polynucleotide stabiliser may comprise citrate (e.g. sodium citrate) in a concentration of from about 1 mM to about 150 mM.
- the polynucleotide stabiliser may comprise citrate (e.g. sodium citrate) in a concentration of from about 1 mM to about 100 mM.
- the polynucleotide stabiliser may comprise citrate (e.g. sodium citrate) in a concentration of from about 1 mM to about 50 mM.
- the polynucleotide stabiliser may comprise citrate (e.g.
- the polynucleotide stabiliser may comprise citrate (e.g. sodium citrate) in a concentration of from about 1 mM to about 20 mM.
- the polynucleotide stabiliser may comprise citrate (e.g. sodium citrate) in a concentration of from about 1 mM to about 15 mM.
- the polynucleotide stabiliser may comprise citrate (e.g. sodium citrate) in a concentration of from about 1 mM to about 10 mM.
- the polynucleotide stabiliser may comprise citrate (e.g. sodium citrate) in a concentration of from about 1 mM to about 9 mM.
- the polynucleotide stabiliser may comprise citrate (e.g. sodium citrate) in a concentration of from about 1 mM to about 8 mM.
- the polynucleotide stabiliser may comprise citrate (e.g. sodium citrate) in a concentration of from about 1 mM to about 7 mM.
- the polynucleotide stabiliser may comprise citrate (e.g. sodium citrate) in a concentration of from about 1 mM to about 6 mM.
- the polynucleotide stabiliser may comprise citrate (e.g. sodium citrate) in a concentration of from about 1 mM to about 5 mM.
- the polynucleotide stabiliser may comprise citrate (e.g.
- the polynucleotide stabiliser may comprise citrate (e.g. sodium citrate) in a concentration of from about 1 mM to about 4 mM.
- the polynucleotide stabiliser may comprise citrate (e.g. sodium citrate) in a concentration of from about 1 mM to about 3 mM.
- the polynucleotide stabiliser may comprise citrate (e.g. sodium citrate) in a concentration of from about 1.2 mM to about 2.8 mM.
- the polynucleotide stabiliser may comprise citrate (e.g. sodium citrate) in a concentration of from about 1.5 mM to about 2.5 mM.
- the polynucleotide stabiliser may comprise citrate (e.g. sodium citrate) in a concentration of about 2 mM.
- the polynucleotide stabiliser may be an RNA stabiliser.
- the polynucleotide stabiliser may be a DNA stabiliser.
- the aqueous formulation may be non-hazardous.
- the aqueous formulation may comprise each of the anionic surfactant, the polynucleotide stabiliser and the buffer at concentrations below the minimum concentrations at which each of the anionic surfactant, the polynucleotide stabiliser and the buffer may be considered hazardous in accordance with REGULATION (EC) No 1272/2008.
- An exemplary aqueous formulation for inactivating a pathogen comprises: an anionic surfactant in a concentration of from about 15 mM to about 35 mM; a polynucleotide stabiliser in a concentration of from about 1 mM to about 3 mM; and a buffer providing a pH of from about 2 to about 4.2.
- the anionic surfactant, polynucleotide stabiliser and buffer may be as further defined herein.
- SOLID MIXTURES Compositions disclosed herein are intended for inactivating a pathogen. This inactivation is typically performed in aqueous solution, e.g. with aqueous formulations provided herein.
- the aqueous solution may also be obtained by contacting an aqueous sample that may comprise a pathogen with a solid mixture comprising anionic surfactant, buffer and polynucleotide stabiliser.
- the aqueous sample may be a biological fluid, such as saliva, sputum, bronchial lavage, tracheal aspirate, nasal wash, urine, semen, lacrimal fluid, synovial fluid, blood, serum, plasma, lymph, cerebrospinal fluid, peritoneal dialysis fluid, or pus.
- compositions of the disclosure may be provided as solid mixtures for improved handling and/or storage, then contacted with water to form an aqueous formulation, when said aqueous solution is desired.
- an aspect of the invention provides a solid mixture comprising: an anionic surfactant in an amount of from about 4% to about 95% by weight; a buffer in an amount of from about 0.4% to about 80% by weight; and a polynucleotide stabiliser in an amount of from about 0.5% to about 70% by weight.
- the anionic surfactant may be in an amount of from about 40% to about 80% by weight; a buffer in an amount of from about 15% to about 40% by weight; and a polynucleotide stabiliser in an amount of from about 1% to about 30% by weight.
- the anionic surfactant may be in an amount of from about 50% to about 70% by weight, from about 55% to about 70% by weight, from about 60% to about 70% by weight, or from about 65% to about 70% by weight. Preferably, the anionic surfactant is in amount of about 70% by weight.
- the buffer may be in an amount of from about 20% to about 30% by weight, or from about 22% to about 28% by weight. Preferably, the buffer is in an amount of about 25% by weight.
- the buffer may be formulated to provide a pH of from about 2 to about 4.2 when the solid mixture is solubilised in water to provide an aqueous solution with the buffer at a concentration of from about 1 mM to about 500 mM (e.g.
- the buffer may be formulated to provide a pH of from about 3 to about 4.2 when the solid mixture is solubilised in water to provide an aqueous solution with the buffer at a concentration of from about 1 mM to about 500 mM (e.g. at a concentration of from about 5 mM to 100 mM).
- the buffer may be formulated to provide a pH of from about 3.3 to about 4.2 when the solid mixture is solubilised in water to provide an aqueous solution with the buffer at a concentration of from about 1 mM to about 500 mM (e.g. at a concentration of from about 5 mM to 100 mM).
- the buffer may be formulated to provide a pH of from about 3.5 to about 4.2 when the solid mixture is solubilised in water to provide an aqueous solution with the buffer at a concentration of from about 1 mM to about 500 mM (e.g. at a concentration of from about 5 mM to 100 mM).
- the buffer may be formulated to provide a pH of from about 3 to about 4 when the solid mixture is solubilised in water to provide an aqueous solution with the buffer at a concentration of from about 1 mM to about 500 mM (e.g. at a concentration of from about 5 mM to 100 mM).
- the buffer may be formulated to provide a pH of from about 3.5 to about 4 when the solid mixture is solubilised in water to provide an aqueous solution with the buffer at a concentration of from about 1 mM to about 500 mM (e.g. at a concentration of from about 5 mM to 100 mM).
- the buffer may be formulated to provide a pH of from about 3.2 to about 3.8 when the solid mixture is solubilised in water to provide an aqueous solution with the buffer at a concentration of from about 1 mM to about 500 mM (e.g. at a concentration of from about 5 mM to 100 mM).
- the buffer may be formulated to provide a pH of from about 3.2 to about 3.6 when the solid mixture is solubilised in water to provide an aqueous solution with the buffer at a concentration of from about 1 mM to about 500 mM (e.g. at a concentration of from about 5 mM to 100 mM).
- the buffer may be formulated to provide a pH of from about 3.4 to about 3.8 when the solid mixture is solubilised in water to provide an aqueous solution with the buffer at a concentration of from about 1 mM to about 500 mM (e.g. at a concentration of from about 5 mM to 100 mM).
- the buffer may be formulated to provide a pH of from about 3.4 to about 3.6 when the solid mixture is solubilised in water to provide an aqueous solution with the buffer at a concentration of from about 1 mM to about 500 mM (e.g. at a concentration of from about 5 mM to 100 mM).
- the buffer may be formulated to provide a pH of about 3.5 when the solid mixture is solubilised in water to provide an aqueous solution with the buffer at a concentration of from about 1 mM to about 500 mM (e.g. at a concentration of from about 5 mM to 100 mM).
- the polynucleotide stabiliser may be in an amount of from about 2% to about 20% by weight, from about 2% to about 15% by weight, from about 2% to about 10% by weight, from about 2% to about 9% by weight, from about 2% to about 8% by weight, from about 2% to about 7% by weight, from about 2% to about 6% by weight, or from about 2% to about 5% by weight.
- the polynucleotide stabiliser is in an amount of about 5% by weight.
- the anionic surfactant is in an amount of from about 50% to about 70% by weight; the buffer is in an amount of from about 20% to about 30% by weight; and the polynucleotide stabiliser is in an amount of from about 2% to about 20% by weight.
- Each of the anionic surfactant, buffer and polynucleotide stabiliser may be selected as disclosed elsewhere herein. USES AND METHODS FOR INACTIVATION / PRESERVATION [0085] Formulations and mixtures of the invention may be used for the inactivation of a pathogen and/or preservation of pathogen polynucleotides. Accordingly, also disclosed are relevant uses and methods of using the formulations and mixtures.
- An embodiment provides use of an aqueous formulation of the invention for the inactivation of a pathogen.
- the use may comprise contacting the aqueous formulation with a sample comprising the pathogen.
- the contacting may be performed at any suitable temperature.
- the contacting may be performed at a temperature of from about 2 °C to about 40 °C, for example at a temperature of from about 10 °C to about 30 °C, such as room temperature.
- the pathogen may release pathogen polynucleotides into the solution after contacting.
- the use may further comprise the preservation of pathogen polynucleotides, e.g. during storage or transport after said contacting.
- the polynucleotide may be RNA or DNA.
- the polynucleotide may be RNA.
- the polynucleotide may be DNA.
- the use may further comprise identifying the pathogen, e.g. by sequencing the pathogen polynucleotides.
- An embodiment provides use of an aqueous formulation of the first aspect for the preservation of pathogen polynucleotides.
- the polynucleotide may be RNA or DNA.
- the polynucleotide may be RNA.
- the polynucleotide may be DNA.
- the use may comprise contacting the aqueous formulation with the pathogen polynucleotides.
- the use may comprise maintaining the aqueous formulation (e.g.
- An embodiment provides a method of inactivating a pathogen, the method comprising contacting a sample containing the pathogen with a formulation of the invention. The contacting may be performed at any suitable temperature.
- the contacting may be performed at a temperature of from about 2 °C to about 40 °C, for example at a temperature of from about 10 °C to about 30 °C, such as room temperature.
- the pathogen may release pathogen polynucleotides into the solution after contacting.
- the polynucleotide may be RNA or DNA.
- the polynucleotide may be RNA.
- the polynucleotide may be DNA.
- the method may further comprise the preservation of pathogen polynucleotides, e.g. during storage or transport after said contacting.
- the method may further comprise analysis of the sample and identifying the pathogen.
- the method of analysis may comprise sequencing the pathogen polynucleotides.
- An embodiment provides a method of preserving pathogen polynucleotides, the method comprising contacting a sample containing the pathogen with a formulation of the first aspect to provide a contacted sample.
- the polynucleotide may be RNA or DNA.
- the polynucleotide may be RNA.
- the polynucleotide may be DNA.
- the method may comprise storing the contacted sample.
- the storing may comprise maintaining the aqueous formulation after said contacting at a temperature of from about -80 °C to about 40 °C.
- the storing comprises maintaining the aqueous formulation after said contacting at a temperature of from about 2 °C to about 40 °C, for example at a temperature of from about 10 °C to about 30 °C, such as room temperature.
- the method may further comprise analysis of the sample and identifying a pathogen, e.g. by sequencing the pathogen polynucleotides.
- An embodiment provides use of a solid mixture of the invention for the inactivation of a pathogen.
- the use may comprise contacting an aqueous sample containing the pathogen with the solid mixture.
- the contacting may be performed at any suitable temperature.
- the contacting may be performed at a temperature of from about 2 °C to about 40 °C, for example at a temperature of from about 10 °C to about 30 °C, such as room temperature.
- the pathogen may release pathogen polynucleotides into the solution after contacting.
- the use may further comprise the preservation of pathogen polynucleotides, e.g. during storage or transport after said contacting.
- the polynucleotide may be RNA or DNA.
- the polynucleotide may be RNA.
- the polynucleotide may be DNA.
- the use may further comprise identifying the pathogen, e.g. by sequencing the pathogen polynucleotides.
- An embodiment provides a use of solid mixture of the invention for the preservation of pathogen polynucleotides.
- the use comprises contacting an aqueous sample containing the pathogen with the solid mixture.
- the polynucleotide may be RNA or DNA.
- the polynucleotide may be RNA.
- the polynucleotide may be DNA.
- the use may comprise contacting the aqueous formulation with the pathogen polynucleotides.
- the use may comprise maintaining the aqueous formulation (e.g. the aqueous formulation after said contacting) at a temperature of from about -80 °C to about 40 °C.
- the use may comprise maintaining the aqueous formulation (e.g.
- An embodiment provides a method of inactivating a pathogen, the method comprising contacting an aqueous sample containing the pathogen with a solid mixture of the invention.
- the contacting may be performed at any suitable temperature.
- the contacting may be performed at a temperature of from about 2 °C to about 40 °C, for example at a temperature of from about 10 °C to about 30 °C, such as room temperature.
- the pathogen may release pathogen polynucleotides into the solution after contacting.
- the polynucleotide may be RNA or DNA.
- the polynucleotide may be RNA.
- the polynucleotide may be DNA.
- the method may further comprise the preservation of pathogen polynucleotides, e.g. during storage or transport after said contacting.
- the method may further comprise analysis of the sample and identifying the pathogen.
- the method of analysis may comprise sequencing the pathogen polynucleotides.
- An embodiment provides a method of preserving pathogen polynucleotides, the method comprising contacting an aqueous sample containing the pathogen with a solid mixture of the invention to provide a contacted sample.
- the polynucleotide may be RNA or DNA.
- the polynucleotide may be RNA.
- the polynucleotide may be DNA.
- the method may comprise storing the contacted sample.
- the storing may comprise maintaining the aqueous formulation after said contacting at a temperature of from about -80 °C to about 40 °C.
- the storing may comprise maintaining the aqueous formulation after said contacting at a temperature of from about 2 °C to about 40 °C, for example at a temperature of from about 10 °C to about 30 °C, such as room temperature.
- the method may further comprise analysis of the sample and identifying a pathogen, e.g.
- the pathogen may be a virus, a bacterium, a fungus, or a parasite.
- the pathogen may be selected from coronaviruses, rotaviruses, noroviruses, enteroviruses, hepatitis viruses, herpesviruses, papillomaviruses, arboviruses (e.g.
- Candida auris Trichomonas vaginalis, Listeria monocytogenes, Bacillus anthracis, Yersinia pestis, Francisella spp, Neisseria gonorrhoea, Neisseria meningitidis, Salmonella spp, Shigella spp, Campylobacter spp, Fusobacterium necrophorum, Mycobacterium spp, Legionella pneumophila, Giardia duodenalis, Cryptosporidium spp, Helicobacter pylori, and Treponema pallidum.
- the pathogen may be a virus or a bacterium.
- the pathogen may be selected from coronaviruses, rotaviruses, noroviruses, enteroviruses, hepatitis viruses, herpesviruses, papillomaviruses, arboviruses (e.g.
- the pathogen may be a virus, e.g. an enveloped or non-enveloped virus.
- the enveloped or non-enveloped virus may be selected from: coronaviruses, rotaviruses, noroviruses, enteroviruses, hepatitis viruses, herpesviruses, papillomaviruses, arboviruses (e.g. West Nile virus, Zika virus, Dengue virus), ebolaviruses, orthomyxoviruses, paramyxoviruses, rabies virus, parechovirus, or rubella virus.
- the pathogen may be an enveloped virus (e.g.
- the enveloped virus may be an influenza virus (e.g. IAV, IBV, ICV, IDV).
- the enveloped virus may be a coronavirus.
- the pathogen may be a coronavirus.
- the pathogen may be selected from severe acute respiratory syndrome coronavirus (SARS-CoV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Middle East respiratory syndrome coronavirus (MERS-CoV), human coronavirus OC43 (HCoV-OC43), human coronavirus HKU1 (HCoV- HKU1), human coronavirus 229E (HCoV-229E), and human coronavirus NL63 (HCoV- NL63), or any variants thereof.
- the pathogen may be severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), or a variant thereof.
- the pathogen may be a bacterium.
- the bacterium may be a Clostridium, a Pseudomonas, an Escherichia, a Klebsiella, an Enterococcus, an Enterobacter, a Serratia, a Stenotrophomonas, an Aeromonas, a Morganella, a Yersinia, a Salmonella, a Proteus, a Pasteurella, a Haemophilus, a Citrobacter, a Burkholderia, a Brucella, a Moraxella, a Mycobacterium, a Streptococcus, a Chlamydia, a Mycoplasma, a Bordatella, a Listeria, a Bacillus, a Francisella, a Neisseria, a Shigella, a Campylobacter, a Fusobacterium, a Legionella, a Helicobacter, a Streptococcus, or a Staphylococcus.
- the bacterium may be an Escherichia (e.g. Escherichia coli) or a Staphylococcus (e.g. a Staphylococcus aureus).
- the pathogen may be a fungus.
- the fungus may be a Blastomyces, a Coccidioides, a Paracoccidioides, a Histoplasma, a Cryptococcus, a Trichophyton, a Microsporum, a Mucor, an Aspergillus, a Sporothrix, or a Talaromyces.
- An embodiment provides a method of identifying a pathogen, comprising contacting a sample containing a suspected pathogen with an aqueous formulation of the invention to provide a sample solution comprising suspected pathogen polynucleotides; optionally storing and/or transporting the sample solution; separating the suspected pathogen polynucleotides from the solution; and subjecting the suspected pathogen polynucleotides to a detection process; and identifying said suspected pathogen, if present, based on the detected pathogen polynucleotides.
- Another embodiment provides a method of identifying a pathogen, comprising contacting an aqueous sample containing a suspected pathogen with a solid mixture of the invention to provide a sample solution comprising suspected pathogen polynucleotides; optionally storing and/or transporting the sample solution; separating the suspected pathogen polynucleotides from the solution; and subjecting the suspected pathogen polynucleotides to a detection process; and identifying said suspected pathogen, if present, based on the detected pathogen polynucleotides.
- the detection process may comprise polymerase chain reaction (PCR) amplification.
- the detection process may comprise quantitative polymerase chain reaction (qPCR).
- the detection process may comprise reverse-transcription polymerase chain reaction (e.g. using reverse transcriptase, to create complementary DNA (cDNA) copies of the RNA, then performing qPCR with that cDNA).
- KITS e.g. using reverse transcriptase, to create complementary DNA (cDNA) copies of the RNA, then performing qPCR with that cDNA.
- Formulations and mixtures of the disclosure are useful in the inactivation of pathogens and/or stabilisation of pathogen nucleic acids. Accordingly, the formulations and mixtures of the invention may be provided in containers suitable for use with individual or pooled samples comprising (suspected) pathogen. Such containers may then be used for the inactivation of pathogens and/or stabilisation of pathogen nucleic acids prior to analysis of the samples for detection of the (suspected) pathogen.
- kits comprising a container comprising an aqueous formulation of the invention or a solid mixture of the invention.
- the kit may also comprise a sampling apparatus.
- the sampling apparatus may comprise a swab and/or funnel.
- the container may be configured such that, after sampling, the container comprises the sample in addition to the aqueous formulation or solid mixture.
- the container may be sealable after sampling.
- the container may have a volume of less than about 50 mL, less than about 40 mL, less than about 30 mL, less than about 20 mL, less than about 10 mL, or less than about 5 mL.
- the container may have a volume of at least about 0.1 mL, at least about 0.5 mL, or at least about 1 mL.
- the container may have a volume of from about 0.1 mL to about 50 mL.
- the container may have a volume of from about 0.5 mL to about 20 mL.
- the container may have a volume of from about 1 mL to about 10 mL.
- the kit may further comprise may further comprise at least one label.
- the label may comprise an ID to assist tracking of the container after sampling.
- the kit may further comprise packaging, wherein the container and optionally other kit components are provided within the packaging.
- SARS-CoV-2 has a structure as illustrated in Figure 1, which includes a lipid envelope (E) 10 and three structural proteins: spike glycoprotein (S) 20, membrane protein (M) 30, and nucleocapsid (N) 40; as well as RNA 50 and hemagglutinin esterase-dimer (HE) 60.
- the overall virus is approximately 100 nm in size. Viral entry into host cells is mediated by spike glycoprotein 20.
- Sodium dodecyl sulfate (SDS) disrupts the lipid envelope (E) 10, and binds to both membrane and non-membrane proteins. SDS binding is also cooperative so binding of one monomer encourages the binding of more.
- SDS sulphate region disrupts non-covalent bonds and the hydrocarbon tail dissolves hydrophobic regions in the structural proteins causing them to lose their conformational shape and function.
- the formulation is also at a low pH (3.5) and acid- induced protein unfolding of effected salt bridges and hydrogen bonds typically occurs at pH values ⁇ 5.
- S protein alteration by denaturation in an SDS / low pH environment renders the virus unable to bind to host cells.
- SDS at low pH (below pH 4) is shown to reduce the critical micellar concentration (CMC), which encourages micelles to form at a lower concentration than normal.
- CMC critical micellar concentration
- RNA is preserved in the formulation by a combination of lower pH and sodium citrate. Without wishing to be bound by theory, it is thought that the sodium ions create a temporary attraction between sodium and the phosphate backbone of RNA.
- RNA is most stable around pH 4.
- the RNA is temporarily neutralized and sodium citrate in solution also acts as a strong chelating agent, thereby preventing oxidation and inactivating metal ion-dependent nucleases which would otherwise degrade the target RNA.
- Example 4 Inactivation of SARS-CoV-2 [00125] A high titre stock of the SARS-CoV-2 strain England/2/2020 was spiked into the formulation of Example 2. The stock of virus has a titre of 2.5 x 10 7 pfu/mL. A viral plaque assay was then conducted on Vero E6 cells, along with a triple passaging assay on Vero V1 cells. No virus was detected in either assay.
- Example 5 SARS-CoV-2 RNA stability study [00126] Tubes containing the formulation of Example 2 were spiked with a high titre stock of the SARS-CoV-2 strain England/2/2020. The tubes were then stored for five days at room temperature followed by five days in the refrigerator. PCR was conducted throughout to determine stability of viral RNA in the medium. Over the 10-day storage period, there was no significant difference in cycle threshold value for N gene, S gene or ORF1a gene (all values were within 1 CT of time 0), thus indicating no significant degradation of RNA over time.
- Example 6 Human RNA stability study [00127] Three tubes were prepared containing the formulation of Example 2. The tubes were spiked with 8 ⁇ L of total human RNA that had been previously diluted 1:10 with purified water.
- the tubes were run through extraction using the MagMAX VP NAI II Kit on a KingFisher Flex system. The elution from each extraction was run once each on real- time PCR using the TaqPATH master mix and ACTB TaqMan primers and probes. The tubes of the formulation + RNA were then moved to a 30°C incubator. The tubes were sampled again at 3 days. At this time 250 ⁇ L aliquots were refrigerated at 4°C. The sample tubes were replaced in the 30°C incubator and sampled again at the 5 day timepoint before being moved into the refrigerator. The aliquots taken previously were sampled after 3 days in the refrigerator, and the sample tubes were sampled after 6 days in the refrigerator.
- Table 2 Results from RNA stability study (a) Time 0 RNA Stability (b) 3 days at 30°C RNA Stability (c) 5 days at 30°C RNA Stability (d) 3 days at 30°C + 3 days at 2-8°C RNA Stability (e) 5 days at 30°C + 5 days at 2-8°C RNA Stability [00129] At all timepoints (a) to (e) the formulation showed ⁇ 1 CT difference when compared to Time 0, indicating no significant degradation of RNA over time.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Provided herein is an aqueous formulation for inactivating a pathogen. The aqueous formulation comprises an anionic surfactant in a concentration of from about 15 mM to about 70 mM, a buffer providing a pH of from about 2 to about 4.2, and a polynucleotide stabiliser in a concentration of from about 1 mM to about 200 mM. Also provided is a solid mixture comprising an anionic surfactant in an amount of from about 50% to about 70% by weight; a buffer in an amount of from about 20% to about 30% by weight; and a polynucleotide stabiliser in an amount of from about 2% to about 20% by weight. The aqueous formulation and solid mixture may be used for the inactivation of pathogens, for example viruses, and for preserving DNA or RNA. Methods of identifying pathogen may also utilise the aqueous formulation and solid mixture. The aqueous formulation or solid mixture may be provided in a container, e.g. for a kit.
Description
FORMULATION [0001] This invention relates to a formulation for inactivating a pathogen, and more particularly to a formulation comprising an anionic surfactant, a buffer and a polynucleotide stabiliser. The invention also relates to a method of inactivating a pathogen. Also provided are uses of the formulations for the inactivation of pathogens, for example viruses, and for preserving DNA or RNA. BACKGROUND [0002] Infectious disease testing is an important tool in modern medicine. Interest in this field has grown substantially following the emergence of coronavirus disease 2019 (COVID-19) as a global pandemic. Caused by the SARS-CoV-2 virus, COVID-19 has caused death or severe illness in millions of people worldwide and significantly impacted global economies. Accordingly, health authorities worldwide have employed molecular testing in an attempt to bring the pandemic under control. [0003] Molecular detection of infectious diseases using amplification methods such as PCR requires the collection of a sample which contains infectious viruses, bacteria or fungi. These pathogens can remain viable in the sample, posing an infection risk to those handling it during transport to, or within, the laboratory. For that reason, it is desirable to inactivate the sample as soon as possible to remove the risk of infection whilst maintaining the structure of target genetic material. Without inactivation, samples in the laboratory, especially those containing respiratory or high-containment pathogens, need to be handled inside a safety cabinet, limiting workspace and throughput. It is also important that the sample collection and inactivation method avoid (or at least minimise) degradation of the nucleic acid material, to ensure efficient molecular detection. [0004] There are several known methods for inactivation of biological materials. The most commonly used are heat-inactivation and chemical inactivation (see, e.g., “Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products”, WHO Technical Report, Series No.924, 2004, Annex 4; E. Patterson et al., The Journal of Infectious Diseases, Volume 222, Issue 9, 1 November 2020, Pages 1462–1467; G. Kampf et al., Journal of Hospital Infection, 2020, 105, 348- 349). Whilst effective, both heat and chemical inactivation add an extra time-consuming step to the laboratory workflow. [0005] Collection and transport media are now available that chemically inactivate the pathogen within the sample tube before arrival at the laboratory. Most of these media utilise chemicals that have historically been used in protein study or nucleic acid extraction
processes, such as sodium dodecyl sulphate and guanidine isothiocyanate (see, e.g., R. Boom et al., Journal of Clinical Microbiology, 1990, 28, 3, 495-503). However, these known media formulations contain these compounds at concentrations that are considered toxic, corrosive, irritant or harmful to the environment and therefore must be handled cautiously. For example, a commonly used chemical inactivator, guanidine isothiocyanate (see, e.g., US8293467 B2, US9683256 B2), releases toxic cyanide gas if mixed with bleach or oxidisers (“Transport Media Safety Risk - Use Compatible Transport Media with SARS-CoV-2 Tests that Use Bleach - Letter to Clinical Laboratory Staff and Health Care Providers”, U.S Food and Drug Administration, 6 April 2020, accessed 21 May 2021 at https://www.fda.gov/medical-devices/letters-health-care-providers/transport-media-safety- risk-use-compatible-transport-media-sars-cov-2-tests-use-bleach-letter). [0006] There is accordingly a need to develop further formulations for inactivating pathogens. It is an object of the invention to develop an effective means and methods for inactivating pathogens (e.g. SARS-CoV-2) which is non-hazardous and/or capable of preserving the structure of the pathogenic genetic material during transport to enable molecular detection of infectious diseases. BRIEF SUMMARY OF THE DISCLOSURE [0007] In accordance with a first aspect of the present invention there is provided an aqueous formulation for inactivating a pathogen, the aqueous formulation comprising: an anionic surfactant in a concentration of from about 15 mM to about 70 mM; a polynucleotide stabiliser in a concentration of from about 1 mM to about 200 mM; and a buffer providing a pH of from about 2 to about 4.2. [0008] A second aspect of the invention provides a use of an aqueous formulation of the first aspect for the inactivation of a pathogen, optionally wherein the use further comprises the preservation of pathogen polynucleotides. [0009] A third aspect of the invention provides a use of an aqueous formulation of the first aspect for the preservation of pathogen polynucleotides. The polynucleotide may be RNA or DNA. The polynucleotide may be RNA. The polynucleotide may be DNA. [0010] A fourth aspect of the invention provides a method of inactivating a pathogen, the method comprising contacting a sample containing the pathogen with a formulation of the first aspect. [0011] A fifth aspect of the invention comprises a method of preserving pathogen polynucleotides, the method comprising contacting a sample containing the pathogen with a formulation of the first aspect to provide a contacted sample, and optionally storing the contacted sample.
[0012] A sixth aspect of the invention provides a solid mixture comprising: an anionic surfactant in an amount of from about 50% to about 70% by weight; a buffer in an amount of from about 20% to about 30% by weight; and a polynucleotide stabiliser in an amount of from about 2% to about 20% by weight. [0013] A seventh aspect of the invention provides a use of a solid mixture of the sixth aspect for the inactivation of a pathogen. The use comprises contacting an aqueous sample containing the pathogen with the solid mixture. The use may further comprise the preservation of pathogen polynucleotides. [0014] An eighth aspect of the invention provides a use of solid mixture of the sixth aspect for the preservation of pathogen polynucleotides. The use comprises contacting an aqueous sample containing the pathogen with the solid mixture. The polynucleotide may be RNA or DNA. The polynucleotide may be RNA. The polynucleotide may be DNA. [0015] A ninth aspect of the invention provides a method of inactivating a pathogen, the method comprising contacting an aqueous sample containing the pathogen with a solid mixture of the sixth aspect. [0016] A tenth aspect of the invention comprises a method of preserving pathogen polynucleotides, the method comprising contacting an aqueous sample containing the pathogen with a solid mixture of the sixth aspect to provide a contacted sample, and optionally storing the contacted sample. [0017] An eleventh aspect of the invention provides a method of identifying a pathogen, comprising: contacting a sample containing a suspected pathogen with an aqueous formulation of the first aspect to provide a sample solution comprising suspected pathogen polynucleotides; storing and/or transporting the sample solution; separating the suspected pathogen polynucleotides from the solution; subjecting the suspected pathogen polynucleotides to a detection process, and identifying said suspected pathogen, if present, based on the detected pathogen polynucleotides. [0018] A twelfth aspect of the invention provides a method of identifying a pathogen, comprising: contacting an aqueous sample containing a suspected pathogen with a solid mixture of the fifth aspect to provide a sample solution comprising suspected pathogen polynucleotides; storing and/or transporting the sample solution; separating the suspected pathogen polynucleotides from the solution; subjecting the suspected pathogen polynucleotides to a detection process, and identifying said suspected pathogen, if present, based on the detected pathogen polynucleotides.
[0019] A thirteenth aspect of the invention provides a kit comprising: a container comprising an aqueous formulation of the first aspect or a solid mixture of the sixth aspect; and optionally a sterile swab and/or funnel. BRIEF DESCRIPTION OF THE DRAWINGS [0020] Embodiments of the invention are further described hereinafter with reference to the accompanying drawings, in which: Figure 1 is a graphical representation of the SARS-CoV-2 virus structure (see H.F. Florindo et al., Nat. Nanotechnol., 15, 630–645, 2020) Figure 2 shows the interaction of detergent sodium dodecyl sulfate (SDS) with lipid envelopes: (a) illustrates a membrane structure in the absence SDS; (b) illustrates intercalation of detergent monomers into the membrane structure; and (c) illustrates the situation when detergent monomers have solubilised the membrane proteins. (see A. Anandan and A. Vrielink, (2016), ‘Detergents in Membrane Protein Purification and Crystallisation’ in I. Moraes, The Next Generation in Membrane Protein Structure Determination, vol 922, Springer, pages 13-28) DETAILED DESCRIPTION [0021] The abbreviations used herein have their conventional meaning within the chemical and biological arts. [0022] Throughout the description and claims of this specification, the words “comprise” and “contain” and variations of them mean “including but not limited to”, and they are not intended to (and do not) exclude other moieties, additives, components, integers or steps. Throughout the description and claims of this specification, the singular encompasses the plural unless the context otherwise requires. In particular, where the indefinite article is used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise. [0023] Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive. The invention is not restricted to the details of any foregoing embodiments. The invention extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings),
or to any novel one, or any novel combination, of the steps of any method or process so disclosed.
[0024] The reader's attention is directed to all papers and documents which are filed concurrently with or previous to this specification in connection with this application and which are open to public inspection with this specification, and the contents of all such papers and documents are incorporated herein by reference.
[0025] For the avoidance of doubt, it is hereby stated that the information disclosed earlier in this specification under the heading “Background” is relevant to the invention and is to be read as part of the disclosure of the invention.
[0026] All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control.
DEFINITIONS
[0027] The following explanations of terms and methods are provided to better describe the present disclosure and to guide those of ordinary skill in the art in the practice of the present disclosure.
[0028] The term “alkali metal” refers to an element from Group 1 of the periodic table, i.e. lithium, sodium, potassium, rubidium, caesium, and francium. Compounds of the disclosure that comprise an alkali metal may comprise lithium, sodium, potassium, rubidium, or caesium. For example, such a compound may comprise lithium, sodium, or potassium; e.g. the compound may comprise sodium.
[0029] The term “buffer” in the present disclosure refers to a conjugate pair comprising of a Brønsted-Lowry acid (HA) and its conjugate Brønsted-Lowry base (A'). When in solution, the buffer resists change in pH when small amounts of an acid or base are added over a certain range or when the solution is diluted. The amount of resistance to change in pH is dependent on the amount of buffer present. Typically, the buffers of the present invention are acidic buffers comprising an acid and a salt. In these acidic buffers, molecules HA and ions A' are present. When acid is added, the additional protons are removed by the ions A'. When base is added, the additional hydroxide ions are removed by reaction with undissociated acid HA:
A- + H+ → HA
0H- + HA → A- + H20
As a result, the hydrogen ion concentration does not change during dilution of the buffer, and so the buffer will maintain a stable pH. The pH range that a given buffer will maintain is dependent on the pKa of the given HA. [0030] The term “% w/v” refers to the percentage weight of a particular component per unit volume of solution:
[0031] The term “% by weight” refers to the percentage weight of a particular component per unit weight. For example, the % by weight of a solid represents the percentage of the weight that the component is of the total amount of solid. [0032] The concentration (i.e. molarity) of each component of the formulation in mol/L (M) can be calculated based on the % w/v value using the formula below:
[0033] The term “inactivation” of or “inactivating” a pathogen refers to a process of enhancing safety in which the pathogen is intentionally “killed”. The level of inactivation is typically expressed using log reduction factor (LRF), which refers to a quantity of pathogen, expressed on a log 10 scale that is inactivated. For example, an LRF of 4 comprises a 10,000 reduction factor, corresponding to inactivation of 99.99% of the pathogen. Inactivation may comprise > 4 LRF, e.g. inactivation may comprise > 5 LRF. LRF may be measured using a suitable method for the pathogen, for example, using a viral plaque assay, a bacterial plaque assay, or TCID50 assay (where TCID50 is defined as the amount of pathogen that causes the death of 50% of cells). Exemplary viral plaque assay protocols for determining the LRF are described in E. J. Mendoza et al. (Curr. Protoc. Microbiol., 2020, 57, 1) and N. Bracci et al. (PeerJ, 2020, 8, 10639). Exemplary TCID50 assay protocols for determining the LRF are described in C. M. Coleman et al. (Curr. Protoc. Microbiol., 2015, 37, 15E.2.1 - 15E.2.9) and S. J. Smither et al. (Journal of Virological Methods, 2013, 193, 565-571). [0034] The term “hazardous” refers to a substance, mixture of substances, or a process involving substances that, under production, usage, or disposal conditions, make it capable of causing adverse effects to non-pathogenic organisms, depending on the degree of exposure. Whether a substance or mixture of substances are hazardous may be dependent on concentration. An example of the minimum concentrations at which particular substances or mixture of substances may be considered hazardous are disclosed in REGULATION (EC) No 1272/2008 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 16 December 2008 (the entirety of which is incorporated herein by
reference). For example, Table 3.3.3 on page 138 of REGULATION (EC) No 1272/2008 (the content of which is incorporated herein by reference), specifies generic concentration limits of ingredients classified as skin corrosion (Category 1, 1A, 1B or 1C) and/or serious eye damage (Category 1) or eye irritation (Category 2), that trigger classification of the mixture as serious eye damage/eye irritation. When a substance is not hazardous, it may be referred to as “non-hazardous”. [0035] The terms “nucleic acid molecule(s)” or “polynucleotide(s)” refers to any compound(s) and/or substance(s) that comprise a polymer of nucleotides. Each nucleotide is composed of a base, specifically a purine- or pyrimidine base (i.e., cytosine (C), guanine (G), adenine (A), thymine (T) or uracil (U)), a sugar (i.e., deoxyribose or ribose), and a phosphate group. Often, the nucleic acid molecule is described by the sequence of bases, whereby said bases represent the primary structure (linear structure) of a nucleic acid molecule. The sequence of bases is typically represented from 5’ to 3’. Herein, the term nucleic acid molecule encompasses deoxyribonucleic acid (DNA) including, e.g., complementary DNA (cDNA) and genomic DNA, ribonucleic acid (RNA), e.g. messenger RNA (mRNA), synthetic forms of DNA or RNA, and mixed polymers comprising two or more of these molecules. The nucleic acid molecule can be linear or circular. In addition, the term nucleic acid molecule includes both, sense and antisense strands, as well as single stranded and double stranded forms. Moreover, the herein described nucleic acid molecule can contain naturally occurring or non-naturally occurring nucleotides. Examples of non-naturally occurring nucleotides include modified nucleotide bases with derivatized sugars or phosphate backbone linkages or chemically modified residues. [0036] The term “pathogen” refers to any organism which causes a disease. The organism may be a virus, bacterium, fungus, or a parasite. The pathogen may be a virus, for example a coronavirus, a rotavirus, a norovirus, an enterovirus, a hepatitis virus, a herpes virus, a papilloma virus, an arbovirus (e.g. West Nile virus, Zika virus, Dengue virus), an ebolavirus, an orthomyxovirus, a paramyxovirus, a rabies virus, a parecho virus, or a rubella virus. The pathogen may be a bacterium, for example a Clostridium, a Pseudomonas, an Escherichia, a Klebsiella, an Enterococcus, an Enterobacter, a Serratia, a Stenotrophomonas, an Aeromonas, a Morganella, a Yersinia, a Salmonella, a Proteus, a Pasteurella, a Haemophilus, a Citrobacter, a Burkholderia, a Brucella, a Moraxella, a Mycobacterium, a Streptococcus or a Staphylococcus. The pathogen may be a fungus, for example a Candida, a Blastomyces, a Coccidioides, a Paracoccidioides, a Histoplasma, a Cryptococcus, a Trichophyton, a Microsporum, a Mucor, an Aspergillus, a Sporothrix, or a Talaromyces.
[0037] The term “polynucleotide stabiliser” refers to a substance that stabilises and protects cellular and/or pathogen RNA or DNA in solution, in particular substances that chelate metal ions and prevent oxidative activity of nuclease enzymes. Exemplary polynucleotide stabilisers include citrates, ethylenediaminetetraacetic acid (EDTA), ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA), 1,2- cyclohexylenedinitrilo)tetraacetic acid (CDTA), 1,2-bis(o-aminophenoxy)ethane-N,N,N′,N′- tetraacetic acid (BAPTA), 8-hydroxyquinoline, citric acid, tartaric acid, lithium chloride, sodium chloride, and magnesium chloride. [0038] A number of the compounds disclosed herein (e.g. exemplary anionic surfactants, exemplary Brønsted-Lowry base (A-), e.g. exemplary polynucleotide stabilisers) comprise an alkali metal cation, such as sodium. While such compounds may be disclosed with a given alkali metal cation, as the skilled person will appreciate, in aqueous solution the identity of the alkali metal cation does not affect the behaviour of the anion. Thus in such compounds disclosed herein, sodium may be substituted with lithium, potassium, rubidium, or caesium. For example, sodium may be replaced with lithium or potassium. Accordingly, unless the context requires otherwise, disclosure of a compound with any one specific alkali metal cation (such as sodium) also includes disclosure of the corresponding compound with each other specific alkali metal cation (such as lithium, potassium, rubidium, or caesium; e.g. lithium or potassium). FORMULATIONS [0039] In any of the following paragraphs, the term “comprising” may be replaced with the terms “substantially consisting of” or “consisting of” as appropriate. [0040] Formulations of the invention are suitable for the inactivation of pathogens. The formulations described herein comprise (or substantially consist of, or consists of): an anionic surfactant in a concentration of from about 15 mM to about 70 mM; a polynucleotide stabiliser in a concentration of from about 1 mM to about 200 mM; and a buffer providing a pH of from about 2 to about 4.2. [0041] The anionic surfactant may be present in a concentration of at least about 15 mM, at least about 20 mM, at least about 22 mM, or at least about 26 mM. The anionic surfactant may be present in a concentration of no more than about 70 mM, no more than about 60 mM, no more than about 50 mM, no more than about 40 mM, no more than about 35 mM, no more than about 30 mM, no more than about 28 mM, or no more than about 26 mM. [0042] The anionic surfactant may be present in a concentration of from about 15 mM to about 70 mM. The anionic surfactant may be present in a concentration of from about 15
mM to about 50 mM. The anionic surfactant may be present in a concentration of from about 15 mM to about 35 mM. The anionic surfactant may be present in a concentration of from about 15 mM to about 30 mM. The anionic surfactant may be present in a concentration of from about 15 mM to about 28 mM. The anionic surfactant may be present in a concentration of from about 15 mM to about 26 mM. The anionic surfactant may be present in a concentration of from about 20 mM to about 70 mM. The anionic surfactant may be present in a concentration of from about 20 mM to about 50 mM. The anionic surfactant may be present in a concentration of from about 20 mM to about 35 mM. The anionic surfactant may be present in a concentration of from about 20 mM to about 30 mM. The anionic surfactant may be present in a concentration of from about 20 mM to about 28 mM. The anionic surfactant may be present in a concentration of from about 20 mM to about 26 mM. The anionic surfactant may be present in a concentration of from about 22 mM to about 35 mM. The anionic surfactant may be present in a concentration of from about 22 mM to about 30 mM. The anionic surfactant may be present in a concentration of from about 22 mM to about 28 mM. The anionic surfactant may be present in a concentration of from about 24 mM to about 28 mM. The anionic surfactant may be present in a concentration of from about 22 mM to about 26 mM. The anionic surfactant may be present in a concentration of from about 26 mM to about 35 mM. The anionic surfactant may be present in a concentration of from about 26 mM to about 30 mM. The anionic surfactant may be present in a concentration of from about 26 mM to about 28 mM. The anionic surfactant may present in a concentration of about 26 mM. [0043] The anionic surfactant may comprise a species selected from: alkyl sulfates, alkyl ether sulfates, arylalkyl sulfates, alkyl aryl ether sulfates alkyl ester sulfates, alkyl sulfonates, alkyl ether sulfonates, arylalkyl sulfonates, alkyl aryl ether sulfonates, alkyl ester sulfonates, alkyl α-olefin sulfonates, alkyl phosphates, alkyl ether phosphates, arylalkyl phosphates, alkyl aryl ether phosphates, alkyl ester phosphates, alkyl carboxylates, alkylamido carboxylates, alkyl ether carboxylates, arylalkyl carboxylates, alkyl aryl ether carboxylates and alkyl ester carboxylates. The anionic surfactant may comprise a species selected from: alkyl sulfates, alkyl ether sulfates, alkyl aryl ether sulfates alkyl ester sulfates, alkyl sulfonates, alkyl ether sulfonates, alkyl aryl ether sulfonates, alkyl ester sulfonates, alkyl α-olefin sulfonates. The anionic surfactant may comprise a species selected from: alkyl sulfates, alkyl ether sulfates, alkyl aryl ether sulfates, alkyl ester sulfates. The anionic surfactant may comprise a species selected from: alkyl sulfates, alkyl ether sulfates. The anionic surfactant may comprise an alkyl sulfate species. The anionic surfactant may comprise an alkyl ether sulfate species. The anionic surfactant may comprise an alkyl sulfonate species.
[0044] The anionic surfactant may comprise a C4-24 alkyl sulfate, a C4-24 alkyl sulfonate or a C4-24 alkyl ether sulfate. The anionic surfactant may comprise a C6-24 alkyl sulfate, a C6-24 alkyl sulfonate or a C6-24 alkyl ether sulfate. The anionic surfactant may comprise a C8-24 alkyl sulfate, a C8-24 alkyl sulfonate or a C8-24 alkyl ether sulfate. The anionic surfactant may comprise a C8-18 alkyl sulfate, a C8-18 alkyl sulfonate or a C8-18 alkyl ether sulfate. The anionic surfactant may comprise a C10-18 alkyl sulfate, a C10-18 alkyl sulfonate or a C10-18 alkyl ether sulfate. The anionic surfactant may comprise a C10-14 alkyl sulfate, C10-14 alkyl sulfonate or C10-14 alkyl ether sulfate. The anionic surfactant may comprise a C10-14 alkyl sulfate. The anionic surfactant may comprise a C10-14 alkyl sulfonate. The anionic surfactant may comprise a C10-14 alkyl ether sulfate. The anionic surfactant may comprise a C12 alkyl sulfate. [0045] The anionic surfactant may comprise or may be selected from: alkali metal dodecyl sulfate, alkali metal decyl sulfate, alkali metal octyl sulfate, alkali metal hexyl sulfate, alkali metal butyl sulfate, alkali metal 2-butyloctyl sulfate, alkali metal 2-ethylhexyl sulfate, alkali metal 3,7-dimethyloctyl sulfate, alkali metal lauryl sulfate, alkali metal lauryl sarcosinate, ammonium lauryl sulfate, alkali metal laureth sulfate, ammonium laureth sulfate, alkali metal myreth sulfate, alkali metal pareth sulfate, C14-16 alkyl α-olefin sulfonate, alkali metal dodecylbenzene sulfonate, alkali metal octanesulfonate, alkali metal decanesulfonate, alkali metal nonanesulfonate, alkali metal heptanesulfonate, alkali metal hexanesulfonate, alkali metal pentanesulfonate, alkali metal butanesulfonate, alkali metal stearate, dioctyl alkali metal sulfosuccinate. The anionic surfactant may comprise or may be selected from: sodium dodecyl sulfate, sodium decyl sulfate, sodium octyl sulfate, sodium hexyl sulfate, sodium 2-butyloctyl sulfate, sodium 2-ethylhexyl sulfate, sodium 3,7- dimethyloctyl sulfate, sodium lauryl sulfate, sodium lauryl sarcosinate, ammonium lauryl sulfate, sodium laureth sulfate, ammonium laureth sulfate, sodium myreth sulfate, sodium pareth sulfate, C14-16 alkyl α-olefin sulfonate, sodium dodecylbenzene sulfonate, sodium octanesulfonate, sodium decanesulfonate, sodium nonanesulfonate, sodium heptanesulfonate, sodium hexanesulfonate, sodium pentanesulfonate, sodium butanesulfonate, sodium stearate, dioctyl sodium sulfosuccinate. Preferably, the anionic surfactant comprises or is sodium dodecyl sulfate. [0046] Alternatively, the anionic surfactant may be selected from any of the anionic surfactant species identified in WO 2006/062835A2 (in particular the anionic surfactant species identified in WO 2006/062835A2 from page 25, line 24 to page 27, line 18), the contents of which are incorporated herein by reference. [0047] Without wishing to be bound by theory, sodium dodecyl sulfate in an amount of about 35 mM (~ 1% w/v) and higher is considered to be hazardous to the user. It is noted
that sodium dodecyl sulfate is considered a Category 1 hazard for serious eye damage/eye irritation, which according to Table 3.3.3 on page 138 of REGULATION (EC) No 1272/2008 (the content of which is incorporated herein by reference) may be hazardous at a concentration of greater than 1%. Accordingly, in some preferred embodiments the anionic surfactant may comprise (or substantially consist of, or consist of) sodium dodecyl sulfate in a concentration of no more than about 35 mM. The anionic surfactant may comprise sodium dodecyl sulfate in a concentration of from about 15 mM to about 35 mM. The anionic surfactant may comprise sodium dodecyl sulfate in a concentration of from about 20 mM to about 30 mM. The anionic surfactant may comprise sodium dodecyl sulfate in a concentration of from about 22 mM to about 28 mM. The anionic surfactant may comprise sodium dodecyl sulfate in a concentration of about 26 mM. [0048] The anionic surfactant may be sodium dodecyl sulfate in an amount of no more than about 1% w/v. The anionic surfactant may be sodium dodecyl sulfate in an amount of from about 0.5% to about 1% w/v, e.g. from about 0.6% to about 1% w/v, from about 0.7% to about 1% w/v, from about 0.8% to about 1% w/v, or from about 0.9% to about 1% w/v. The anionic may be sodium dodecyl sulfate in an amount of from greater than 0.5% to less than 1% w/v, e.g. from greater than 0.6% to less than 1% w/v, from greater than 0.7% to less than 1% w/v, from greater than 0.8% to less than 1% w/v, from greater than 0.9% to less than 1% w/v. [0049] The anionic surfactant may be sodium dodecyl sulfate in an amount of from about 0.5% to about 0.95% w/v, from about 0.5% to about 0.9% w/v, from about 0.5% to about 0.85% w/v, from about 0.5% to about 0.8% w/v, or from about 0.5% to about 0.75% w/v. The anionic surfactant may be sodium dodecyl sulfate in an amount of from about 0.6% to about 0.95% w/v, from about 0.6% to about 0.9% w/v, from about 0.6% to about 0.85% w/v, from about 0.6% to about 0.8% w/v, or from about 0.6% to about 0.75% w/v. The anionic surfactant may be sodium dodecyl sulfate in an amount of from about 0.7% to about 0.95% w/v, from about 0.7% to about 0.9% w/v, from about 0.7% to about 0.85% w/v, from about 0.7% to about 0.8% w/v, or from about 0.7% to about 0.75% w/v. The anionic surfactant may be sodium dodecyl sulfate in an amount of about 0.75% w/v. [0050] It has been shown that high and low pH can affect the viability of pathogens, in particular SARS coronaviruses, however this effect is temperature dependent (M.E.R. Darnell, et al., J. Virol. Methods, 2004 Oct; 121(1): 85–91). In addition, pH control alone is not a reliable method of inactivation as neutralisation is likely to occur due to natural buffering of the sample. We have identified that provision of a low pH in the formulations
provided herein, in particular in combination with the specified levels of anionic surfactant, provides a significant level of pathogen inactivation. [0051] The aqueous formulation may have a pH of about from about 3 to about 4.2. The aqueous formulation may have a pH of from about 3 to about 4. The aqueous formulation may have a pH of from about 3.2 to about 3.8. The aqueous formulation may have a pH of from about 3.2 to about 3.6. The aqueous formulation may have a pH of from about 3.4 to about 3.8. The aqueous formulation may have a pH of from about 3.4 to about 3.6. The aqueous formulation may have a pH of about 3.5. [0052] The aqueous formulation may have a pH of at least about 3, about 3.1, about 3.2, about 3.3, about 3.4, or about 3.5. For example, the aqueous formulation may have a pH of at least about 3.4 or about 3.5; e.g. the aqueous formulation may have a pH of at least about 3.5. The aqueous formulation may have a pH of not more than about 4.2, about 4.1, or about 4. The aqueous formulation may have a pH of about from about 3.2 to about 4.2. The aqueous formulation may have a pH of about from about 3.5 to about 4.2. [0053] The anionic surfactant may be sodium dodecyl sulfate and the aqueous formulation may have a pH of from about 3 to about 4. The anionic surfactant may be sodium dodecyl sulfate and the aqueous formulation may have a pH of from about 3.2 to about 3.8. The anionic surfactant may be sodium dodecyl sulfate and the aqueous formulation may have a pH of from about 3.2 to about 3.6. The anionic surfactant may be sodium dodecyl sulfate and the aqueous formulation may have a pH of from about 3.4 to about 3.8. The anionic surfactant may be sodium dodecyl sulfate and the aqueous formulation may have a pH of from about 3.4 to about 3.6. The anionic surfactant may be sodium dodecyl sulfate and the aqueous formulation may have a pH of about 3.5. [0054] The anionic surfactant may be sodium dodecyl sulfate and the aqueous formulation may have a pH of from about 3.2 to about 4.2. The anionic surfactant may be sodium dodecyl sulfate and the aqueous formulation may have a pH of from about 3.5 to about 4.2. [0055] The inventors have surprisingly found that the use of sodium dodecyl sulfate at low pH, e.g. a pH of less than 4.5, has the combined effect of inactivating pathogens while preserving the pathogen polynucleotides. It is believed that a pH of less than 2 will cause degradation of the pathogen nucleotides. Accordingly, the aqueous formulations of the present invention advantageously have pH of from about 2 to about 4.2. Formulations having a pH of about 3.5 may be preferred. [0056] The buffer may comprise or may be selected from a species having a suitable pKa value to maintain a pH of from about 2 to about 4.2 (e.g. from about 3 to about 4.2,
from about 3 to about 4, from about 3.2 to about 3.8, or about 3.5). The buffer may comprise or may be selected from: lactate/lactic acid, glycine – hydrochloric acid, acetate/acetic acid and citrate/citric acid. The buffer may comprise or may be selected from: lactate/lactic acid and glycine – hydrochloric acid. The buffer may comprise or may be lactate/lactic acid. The buffer may comprise or may be glycine – hydrochloric acid. [0057] The lactate, acetate and citrate species of the buffer may comprise lactic acid, acetic acid and citric acid respectively and salts thereof. For example, the lactate, acetate and citrate species may comprise alkali metal salts thereof (e.g. lithium, sodium, and/or potassium). Preferably, the buffer is sodium lactate/lactic acid. However, the sodium can be replaced with another alkali metal (e.g. lithium, potassium) as the counter ion where possible. [0058] The buffer may be in a concentration of from about 1 mM to about 500 mM. The buffer may be in a concentration of from about 5 mM to about 150 mM. The buffer may be in a concentration of from about 5 mM to about 100 mM. The buffer may be in a concentration of from about 5 mM to about 50 mM. The buffer may be in a concentration of from about 5 mM to about 25 mM. The buffer may be in a concentration of from about 5 mM to about 15 mM. The buffer may be in a concentration of from about 5 mM to about 10 mM. The buffer may be in a concentration of about 10 mM. [0059] The buffer may be lactate/lactic acid (e.g. sodium lactate/lactic acid) in a concentration sufficient to maintain a pH of from about 2 to about 4.2 (e.g. from about 3 to about 4.2, from about 3 to about 4, from about 3.2 to about 3.8, or about 3.5). The buffer may be lactate/lactic acid (e.g. sodium lactate/lactic acid) in a concentration of from about 5 mM to about 150 mM, from about 5 mM to about 100 mM, from about 5 mM to about 50 mM, from about 5 mM to about 25 mM, from about 5 mM to about 15 mM, or from about 5 mM to about 10 mM. The buffer may be lactate/lactic acid (e.g. sodium lactate/lactic acid) in a concentration of about 10 mM. [0060] Where the buffer is lactate/lactic acid (e.g. sodium lactate/lactic acid), the lactate may be present in an amount of from about 0.03% to about 0.07% w/v (e.g. about 0.05% w/v) and the lactic acid may be present in an amount of from about 0.2% to about 0.25% w/v (e.g. about 0.22% w/v). [0061] The polynucleotide stabiliser may be in a concentration of from about 1 mM to about 200 mM. The polynucleotide stabiliser may be in a concentration of from about 1 mM to about 150 mM. The polynucleotide stabiliser may be in a concentration of from about 1 mM to about 100 mM. The polynucleotide stabiliser may be in a concentration of from about 1 mM to about 50 mM. The polynucleotide stabiliser may be in a concentration of from about 1 mM to about 25 mM. The polynucleotide stabiliser may be in a
concentration of from about 1 mM to about 20 mM. The polynucleotide stabiliser may be in a concentration of from about 1 mM to about 15 mM. The polynucleotide stabiliser may be in a concentration of from about 1 mM to about 10 mM. The polynucleotide stabiliser may be in a concentration of from about 1 mM to about 9 mM. The polynucleotide stabiliser may be in a concentration of from about 1 mM to about 8 mM. The polynucleotide stabiliser may be in a concentration of from about 1 mM to about 7 mM. The polynucleotide stabiliser may be in a concentration of from about 1 mM to about 6 mM. The polynucleotide stabiliser may be in a concentration of from about 1 mM to about 5 mM. The polynucleotide stabiliser may be in a concentration of from about 1 mM to about 4 mM. The polynucleotide stabiliser may be in a concentration of from about 1 mM to about 3 mM. The polynucleotide stabiliser may be in a concentration of from about 1.2 mM to about 2.8 mM. The polynucleotide stabiliser may be in a concentration of from about 1.5 mM to about 2.5 mM. The polynucleotide stabiliser may be in a concentration of about 2 mM. [0062] The polynucleotide stabiliser may comprise or be selected from: citrate, ethylenediaminetetraacetic acid (EDTA), ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′- tetraacetic acid (EGTA), 1,2-cyclohexylenedinitrilo)tetraacetic acid (CDTA), 1,2-bis(o- aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid (BAPTA), 8-hydrozyquinoline, citric acid, tartaric acid, lithium chloride, sodium chloride, and magnesium chloride. Preferably, the polynucleotide stabiliser is citrate (e.g. sodium citrate). [0063] The polynucleotide stabiliser may comprise citrate (e.g. sodium citrate) in a concentration of from about 1 mM to about 150 mM. The polynucleotide stabiliser may comprise citrate (e.g. sodium citrate) in a concentration of from about 1 mM to about 100 mM. The polynucleotide stabiliser may comprise citrate (e.g. sodium citrate) in a concentration of from about 1 mM to about 50 mM. The polynucleotide stabiliser may comprise citrate (e.g. sodium citrate) in a concentration of from about 1 mM to about 25 mM. The polynucleotide stabiliser may comprise citrate (e.g. sodium citrate) in a concentration of from about 1 mM to about 20 mM. The polynucleotide stabiliser may comprise citrate (e.g. sodium citrate) in a concentration of from about 1 mM to about 15 mM. The polynucleotide stabiliser may comprise citrate (e.g. sodium citrate) in a concentration of from about 1 mM to about 10 mM. The polynucleotide stabiliser may comprise citrate (e.g. sodium citrate) in a concentration of from about 1 mM to about 9 mM. The polynucleotide stabiliser may comprise citrate (e.g. sodium citrate) in a concentration of from about 1 mM to about 8 mM. The polynucleotide stabiliser may comprise citrate (e.g. sodium citrate) in a concentration of from about 1 mM to about 7 mM. The polynucleotide stabiliser may comprise citrate (e.g. sodium citrate) in a
concentration of from about 1 mM to about 6 mM. The polynucleotide stabiliser may comprise citrate (e.g. sodium citrate) in a concentration of from about 1 mM to about 5 mM. The polynucleotide stabiliser may comprise citrate (e.g. sodium citrate) in a concentration of from about 1 mM to about 4 mM. The polynucleotide stabiliser may comprise citrate (e.g. sodium citrate) in a concentration of from about 1 mM to about 3 mM. The polynucleotide stabiliser may comprise citrate (e.g. sodium citrate) in a concentration of from about 1.2 mM to about 2.8 mM. The polynucleotide stabiliser may comprise citrate (e.g. sodium citrate) in a concentration of from about 1.5 mM to about 2.5 mM. The polynucleotide stabiliser may comprise citrate (e.g. sodium citrate) in a concentration of about 2 mM. [0064] The polynucleotide stabiliser may be an RNA stabiliser. Alternatively, the polynucleotide stabiliser may be a DNA stabiliser. [0065] The aqueous formulation may be non-hazardous. For example, the aqueous formulation may comprise each of the anionic surfactant, the polynucleotide stabiliser and the buffer at concentrations below the minimum concentrations at which each of the anionic surfactant, the polynucleotide stabiliser and the buffer may be considered hazardous in accordance with REGULATION (EC) No 1272/2008. [0066] An exemplary aqueous formulation for inactivating a pathogen comprises: an anionic surfactant in a concentration of from about 15 mM to about 35 mM; a polynucleotide stabiliser in a concentration of from about 1 mM to about 3 mM; and a buffer providing a pH of from about 2 to about 4.2. The anionic surfactant, polynucleotide stabiliser and buffer may be as further defined herein. SOLID MIXTURES [0067] Compositions disclosed herein are intended for inactivating a pathogen. This inactivation is typically performed in aqueous solution, e.g. with aqueous formulations provided herein. The aqueous solution may also be obtained by contacting an aqueous sample that may comprise a pathogen with a solid mixture comprising anionic surfactant, buffer and polynucleotide stabiliser. The aqueous sample may be a biological fluid, such as saliva, sputum, bronchial lavage, tracheal aspirate, nasal wash, urine, semen, lacrimal fluid, synovial fluid, blood, serum, plasma, lymph, cerebrospinal fluid, peritoneal dialysis fluid, or pus. In addition, compositions of the disclosure may be provided as solid mixtures for improved handling and/or storage, then contacted with water to form an aqueous formulation, when said aqueous solution is desired. [0068] Accordingly, an aspect of the invention provides a solid mixture comprising: an anionic surfactant in an amount of from about 4% to about 95% by weight; a buffer in an
amount of from about 0.4% to about 80% by weight; and a polynucleotide stabiliser in an amount of from about 0.5% to about 70% by weight. The anionic surfactant may be in an amount of from about 40% to about 80% by weight; a buffer in an amount of from about 15% to about 40% by weight; and a polynucleotide stabiliser in an amount of from about 1% to about 30% by weight. [0069] The anionic surfactant may be in an amount of from about 50% to about 70% by weight, from about 55% to about 70% by weight, from about 60% to about 70% by weight, or from about 65% to about 70% by weight. Preferably, the anionic surfactant is in amount of about 70% by weight. [0070] The buffer may be in an amount of from about 20% to about 30% by weight, or from about 22% to about 28% by weight. Preferably, the buffer is in an amount of about 25% by weight. [0071] The buffer may be formulated to provide a pH of from about 2 to about 4.2 when the solid mixture is solubilised in water to provide an aqueous solution with the buffer at a concentration of from about 1 mM to about 500 mM (e.g. at a concentration of from about 5 mM to 100 mM). [0072] The buffer may be formulated to provide a pH of from about 3 to about 4.2 when the solid mixture is solubilised in water to provide an aqueous solution with the buffer at a concentration of from about 1 mM to about 500 mM (e.g. at a concentration of from about 5 mM to 100 mM). [0073] The buffer may be formulated to provide a pH of from about 3.3 to about 4.2 when the solid mixture is solubilised in water to provide an aqueous solution with the buffer at a concentration of from about 1 mM to about 500 mM (e.g. at a concentration of from about 5 mM to 100 mM). [0074] The buffer may be formulated to provide a pH of from about 3.5 to about 4.2 when the solid mixture is solubilised in water to provide an aqueous solution with the buffer at a concentration of from about 1 mM to about 500 mM (e.g. at a concentration of from about 5 mM to 100 mM). [0075] The buffer may be formulated to provide a pH of from about 3 to about 4 when the solid mixture is solubilised in water to provide an aqueous solution with the buffer at a concentration of from about 1 mM to about 500 mM (e.g. at a concentration of from about 5 mM to 100 mM). [0076] The buffer may be formulated to provide a pH of from about 3.5 to about 4 when the solid mixture is solubilised in water to provide an aqueous solution with the buffer at a
concentration of from about 1 mM to about 500 mM (e.g. at a concentration of from about 5 mM to 100 mM). [0077] The buffer may be formulated to provide a pH of from about 3.2 to about 3.8 when the solid mixture is solubilised in water to provide an aqueous solution with the buffer at a concentration of from about 1 mM to about 500 mM (e.g. at a concentration of from about 5 mM to 100 mM). [0078] The buffer may be formulated to provide a pH of from about 3.2 to about 3.6 when the solid mixture is solubilised in water to provide an aqueous solution with the buffer at a concentration of from about 1 mM to about 500 mM (e.g. at a concentration of from about 5 mM to 100 mM). [0079] The buffer may be formulated to provide a pH of from about 3.4 to about 3.8 when the solid mixture is solubilised in water to provide an aqueous solution with the buffer at a concentration of from about 1 mM to about 500 mM (e.g. at a concentration of from about 5 mM to 100 mM). [0080] The buffer may be formulated to provide a pH of from about 3.4 to about 3.6 when the solid mixture is solubilised in water to provide an aqueous solution with the buffer at a concentration of from about 1 mM to about 500 mM (e.g. at a concentration of from about 5 mM to 100 mM). [0081] The buffer may be formulated to provide a pH of about 3.5 when the solid mixture is solubilised in water to provide an aqueous solution with the buffer at a concentration of from about 1 mM to about 500 mM (e.g. at a concentration of from about 5 mM to 100 mM). [0082] The polynucleotide stabiliser may be in an amount of from about 2% to about 20% by weight, from about 2% to about 15% by weight, from about 2% to about 10% by weight, from about 2% to about 9% by weight, from about 2% to about 8% by weight, from about 2% to about 7% by weight, from about 2% to about 6% by weight, or from about 2% to about 5% by weight. Preferably, the polynucleotide stabiliser is in an amount of about 5% by weight. [0083] In an exemplary solid mixture, the anionic surfactant is in an amount of from about 50% to about 70% by weight; the buffer is in an amount of from about 20% to about 30% by weight; and the polynucleotide stabiliser is in an amount of from about 2% to about 20% by weight. [0084] Each of the anionic surfactant, buffer and polynucleotide stabiliser may be selected as disclosed elsewhere herein.
USES AND METHODS FOR INACTIVATION / PRESERVATION [0085] Formulations and mixtures of the invention may be used for the inactivation of a pathogen and/or preservation of pathogen polynucleotides. Accordingly, also disclosed are relevant uses and methods of using the formulations and mixtures. [0086] An embodiment provides use of an aqueous formulation of the invention for the inactivation of a pathogen. The use may comprise contacting the aqueous formulation with a sample comprising the pathogen. The contacting may be performed at any suitable temperature. For example, the contacting may be performed at a temperature of from about 2 °C to about 40 °C, for example at a temperature of from about 10 °C to about 30 °C, such as room temperature. The pathogen may release pathogen polynucleotides into the solution after contacting. The use may further comprise the preservation of pathogen polynucleotides, e.g. during storage or transport after said contacting. The polynucleotide may be RNA or DNA. The polynucleotide may be RNA. The polynucleotide may be DNA. The use may further comprise identifying the pathogen, e.g. by sequencing the pathogen polynucleotides. [0087] An embodiment provides use of an aqueous formulation of the first aspect for the preservation of pathogen polynucleotides. The polynucleotide may be RNA or DNA. The polynucleotide may be RNA. The polynucleotide may be DNA. The use may comprise contacting the aqueous formulation with the pathogen polynucleotides. The use may comprise maintaining the aqueous formulation (e.g. the aqueous formulation after said contacting) at a temperature of from about -80 °C to about 40 °C. Typically, the use may comprise maintaining the aqueous formulation (e.g. the aqueous formulation after said contacting) at a temperature of from about 2 °C to about 40 °C, for example at a temperature of from about 10 °C to about 30 °C, such as room temperature. The use may further comprise identifying the pathogen. [0088] An embodiment provides a method of inactivating a pathogen, the method comprising contacting a sample containing the pathogen with a formulation of the invention. The contacting may be performed at any suitable temperature. For example, the contacting may be performed at a temperature of from about 2 °C to about 40 °C, for example at a temperature of from about 10 °C to about 30 °C, such as room temperature. The pathogen may release pathogen polynucleotides into the solution after contacting. The polynucleotide may be RNA or DNA. The polynucleotide may be RNA. The polynucleotide may be DNA. The method may further comprise the preservation of pathogen polynucleotides, e.g. during storage or transport after said contacting. The method may further comprise analysis of the sample and identifying the pathogen. The method of analysis may comprise sequencing the pathogen polynucleotides.
[0089] An embodiment provides a method of preserving pathogen polynucleotides, the method comprising contacting a sample containing the pathogen with a formulation of the first aspect to provide a contacted sample. The polynucleotide may be RNA or DNA. The polynucleotide may be RNA. The polynucleotide may be DNA. The method may comprise storing the contacted sample. The storing may comprise maintaining the aqueous formulation after said contacting at a temperature of from about -80 °C to about 40 °C. Typically, the storing comprises maintaining the aqueous formulation after said contacting at a temperature of from about 2 °C to about 40 °C, for example at a temperature of from about 10 °C to about 30 °C, such as room temperature. The method may further comprise analysis of the sample and identifying a pathogen, e.g. by sequencing the pathogen polynucleotides. [0090] An embodiment provides use of a solid mixture of the invention for the inactivation of a pathogen. The use may comprise contacting an aqueous sample containing the pathogen with the solid mixture. The contacting may be performed at any suitable temperature. For example, the contacting may be performed at a temperature of from about 2 °C to about 40 °C, for example at a temperature of from about 10 °C to about 30 °C, such as room temperature. The pathogen may release pathogen polynucleotides into the solution after contacting. The use may further comprise the preservation of pathogen polynucleotides, e.g. during storage or transport after said contacting. The polynucleotide may be RNA or DNA. The polynucleotide may be RNA. The polynucleotide may be DNA. The use may further comprise identifying the pathogen, e.g. by sequencing the pathogen polynucleotides. [0091] An embodiment provides a use of solid mixture of the invention for the preservation of pathogen polynucleotides. The use comprises contacting an aqueous sample containing the pathogen with the solid mixture. The polynucleotide may be RNA or DNA. The polynucleotide may be RNA. The polynucleotide may be DNA. The use may comprise contacting the aqueous formulation with the pathogen polynucleotides. The use may comprise maintaining the aqueous formulation (e.g. the aqueous formulation after said contacting) at a temperature of from about -80 °C to about 40 °C. Typically, the use may comprise maintaining the aqueous formulation (e.g. the aqueous formulation after said contacting) at a temperature of from about 2 °C to about 40 °C, for example at a temperature of from about 10 °C to about 30 °C, such as room temperature. The use may further comprise identifying a pathogen, e.g. by sequencing the pathogen polynucleotides. [0092] An embodiment provides a method of inactivating a pathogen, the method comprising contacting an aqueous sample containing the pathogen with a solid mixture of the invention. The contacting may be performed at any suitable temperature. For
example, the contacting may be performed at a temperature of from about 2 °C to about 40 °C, for example at a temperature of from about 10 °C to about 30 °C, such as room temperature. The pathogen may release pathogen polynucleotides into the solution after contacting. The polynucleotide may be RNA or DNA. The polynucleotide may be RNA. The polynucleotide may be DNA. The method may further comprise the preservation of pathogen polynucleotides, e.g. during storage or transport after said contacting. The method may further comprise analysis of the sample and identifying the pathogen. The method of analysis may comprise sequencing the pathogen polynucleotides. [0093] An embodiment provides a method of preserving pathogen polynucleotides, the method comprising contacting an aqueous sample containing the pathogen with a solid mixture of the invention to provide a contacted sample. The polynucleotide may be RNA or DNA. The polynucleotide may be RNA. The polynucleotide may be DNA. The method may comprise storing the contacted sample. The storing may comprise maintaining the aqueous formulation after said contacting at a temperature of from about -80 °C to about 40 °C. Typically, the storing may comprise maintaining the aqueous formulation after said contacting at a temperature of from about 2 °C to about 40 °C, for example at a temperature of from about 10 °C to about 30 °C, such as room temperature. The method may further comprise analysis of the sample and identifying a pathogen, e.g. by sequencing the pathogen polynucleotides [0094] In the uses and methods described herein, the pathogen may be a virus, a bacterium, a fungus, or a parasite. [0095] The pathogen may be selected from coronaviruses, rotaviruses, noroviruses, enteroviruses, hepatitis viruses, herpesviruses, papillomaviruses, arboviruses (e.g. West Nile virus, Zika virus, Dengue virus), ebolaviruses, orthomyxoviruses, paramyxoviruses, rabies virus, parechovirus, rubella virus., Escherichia coli, Staphylococcus aureus, Chlamydia trachomatis, Mycoplasma spp, Bordatella pertussis, Bordatella parapertussis, Streptococcus pyogenes, Streptococcus agalactiae, Candida spp (e.g. Candida auris), Trichomonas vaginalis, Listeria monocytogenes, Bacillus anthracis, Yersinia pestis, Francisella spp, Neisseria gonorrhoea, Neisseria meningitidis, Salmonella spp, Shigella spp, Campylobacter spp, Fusobacterium necrophorum, Mycobacterium spp, Legionella pneumophila, Giardia duodenalis, Cryptosporidium spp, Helicobacter pylori, and Treponema pallidum. [0096] In the uses and methods described herein, the pathogen may be a virus or a bacterium. [0097] The pathogen may be selected from coronaviruses, rotaviruses, noroviruses, enteroviruses, hepatitis viruses, herpesviruses, papillomaviruses, arboviruses (e.g. West
Nile virus, Zika virus, Dengue virus), ebolaviruses, orthomyxoviruses, paramyxoviruses, rabies virus, parechovirus, rubella virus., Escherichia coli, Staphylococcus aureus, Chlamydia trachomatis, Mycoplasma spp, Bordatella pertussis, Bordatella parapertussis, Streptococcus pyogenes, Streptococcus agalactiae, Listeria monocytogenes, Bacillus anthracis, Yersinia pestis, Francisella spp, Neisseria gonorrhoea, Neisseria meningitidis, Salmonella spp, Shigella spp, Campylobacter spp, Fusobacterium necrophorum, Mycobacterium spp, Legionella pneumophila, Giardia duodenalis, Helicobacter pylori, and Treponema pallidum. [0098] The pathogen may be a virus, e.g. an enveloped or non-enveloped virus. The enveloped or non-enveloped virus may be selected from: coronaviruses, rotaviruses, noroviruses, enteroviruses, hepatitis viruses, herpesviruses, papillomaviruses, arboviruses (e.g. West Nile virus, Zika virus, Dengue virus), ebolaviruses, orthomyxoviruses, paramyxoviruses, rabies virus, parechovirus, or rubella virus. [0099] The pathogen may be an enveloped virus (e.g. an enveloped RNA virus, such as the coronavirus illustrated in Figure 1). The enveloped virus may be an influenza virus (e.g. IAV, IBV, ICV, IDV). The enveloped virus may be a coronavirus. [00100] The pathogen may be a coronavirus. The pathogen may be selected from severe acute respiratory syndrome coronavirus (SARS-CoV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Middle East respiratory syndrome coronavirus (MERS-CoV), human coronavirus OC43 (HCoV-OC43), human coronavirus HKU1 (HCoV- HKU1), human coronavirus 229E (HCoV-229E), and human coronavirus NL63 (HCoV- NL63), or any variants thereof. The pathogen may be severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), or a variant thereof. [00101] The pathogen may be a bacterium. The bacterium may be a Clostridium, a Pseudomonas, an Escherichia, a Klebsiella, an Enterococcus, an Enterobacter, a Serratia, a Stenotrophomonas, an Aeromonas, a Morganella, a Yersinia, a Salmonella, a Proteus, a Pasteurella, a Haemophilus, a Citrobacter, a Burkholderia, a Brucella, a Moraxella, a Mycobacterium, a Streptococcus, a Chlamydia, a Mycoplasma, a Bordatella, a Listeria, a Bacillus, a Francisella, a Neisseria, a Shigella, a Campylobacter, a Fusobacterium, a Legionella, a Helicobacter, a Streptococcus, or a Staphylococcus. The bacterium may be an Escherichia (e.g. Escherichia coli) or a Staphylococcus (e.g. a Staphylococcus aureus). [00102] The pathogen may be a fungus. The fungus may be a Blastomyces, a Coccidioides, a Paracoccidioides, a Histoplasma, a Cryptococcus, a Trichophyton, a Microsporum, a Mucor, an Aspergillus, a Sporothrix, or a Talaromyces.
METHODS OF IDENTIFYING A PATHOGEN [00103] An embodiment provides a method of identifying a pathogen, comprising contacting a sample containing a suspected pathogen with an aqueous formulation of the invention to provide a sample solution comprising suspected pathogen polynucleotides; optionally storing and/or transporting the sample solution; separating the suspected pathogen polynucleotides from the solution; and subjecting the suspected pathogen polynucleotides to a detection process; and identifying said suspected pathogen, if present, based on the detected pathogen polynucleotides. [00104] Another embodiment provides a method of identifying a pathogen, comprising contacting an aqueous sample containing a suspected pathogen with a solid mixture of the invention to provide a sample solution comprising suspected pathogen polynucleotides; optionally storing and/or transporting the sample solution; separating the suspected pathogen polynucleotides from the solution; and subjecting the suspected pathogen polynucleotides to a detection process; and identifying said suspected pathogen, if present, based on the detected pathogen polynucleotides. [00105] The detection process may comprise polymerase chain reaction (PCR) amplification. For example, the detection process may comprise quantitative polymerase chain reaction (qPCR). Where the pathogen polynucleotides are RNA, the detection process may comprise reverse-transcription polymerase chain reaction (e.g. using reverse transcriptase, to create complementary DNA (cDNA) copies of the RNA, then performing qPCR with that cDNA). KITS [00106] Formulations and mixtures of the disclosure are useful in the inactivation of pathogens and/or stabilisation of pathogen nucleic acids. Accordingly, the formulations and mixtures of the invention may be provided in containers suitable for use with individual or pooled samples comprising (suspected) pathogen. Such containers may then be used for the inactivation of pathogens and/or stabilisation of pathogen nucleic acids prior to analysis of the samples for detection of the (suspected) pathogen. [00107] An embodiment provides a kit comprising a container comprising an aqueous formulation of the invention or a solid mixture of the invention. [00108] The kit may also comprise a sampling apparatus. The sampling apparatus may comprise a swab and/or funnel. [00109] The container may be configured such that, after sampling, the container comprises the sample in addition to the aqueous formulation or solid mixture. The container may be sealable after sampling.
[00110] The container may have a volume of less than about 50 mL, less than about 40 mL, less than about 30 mL, less than about 20 mL, less than about 10 mL, or less than about 5 mL. The container may have a volume of at least about 0.1 mL, at least about 0.5 mL, or at least about 1 mL. The container may have a volume of from about 0.1 mL to about 50 mL. The container may have a volume of from about 0.5 mL to about 20 mL. The container may have a volume of from about 1 mL to about 10 mL. [00111] While the aqueous solution and (when dissolved in the container) solid mixture are believed to be self-sterilising, the container and (if present) any sampling apparatus may be provided sterile. Providing components of the kit in sterile form prior to sampling reduces the risk of pre-contamination of the kit with pathogen prior to sampling. [00112] The kit may comprise instructions. [00113] The kit may further comprise may further comprise at least one label. The label may comprise an ID to assist tracking of the container after sampling. The kit may further comprise packaging, wherein the container and optionally other kit components are provided within the packaging. EXAMPLES Example 1: Formulations and Testing [00114] The following components were mixed together in the given amounts to provide a formulation of the invention: [00115] The inactivation of four bacteriophages (enveloped T2, M13, Phi-X174 and non- enveloped Phi-6) and two bacteria (Escherichia coli and Staphylococcus aureus) were tested using formulations containing sodium dodecyl sulfate and different buffers (including sodium citrate / citric acid, lactic acid / sodium lactate, glycine – hydrochloric acid and sodium acetate / acetic acid) at different pH values. The pH values tested were from about 3.5 to about 4. The sodium dodecyl sulfate concentration was reduced from 1% to 0.95% to be less hazardous. The formulations were tested at full-strength and also 75% strength. The table below shows the number of viral plaques (PFU/mL) or bacterial colonies (CFU/mL) present following treatment with each formulation. [00116] Table 1: Results for exemplary formulations
[00117] Complete inactivation of all phages and bacteria was achieved using the full- strength formulations. At 75% strength, the formulations containing glycine, acetate and lactate buffers at pH 3.5 gave complete inactivation. Thus, low pH contributes further to inactivation. Without wishing to be bound by any theory, it is believed that the improved inactivation at low pH (compared to higher pH) is due to the low pH having an activating effect on sodium dodecyl sulfate and similar anionic surfactants. Example 2: Manufacture of formulations [00118] The following components were mixed together in the given amounts to provide a formulation of the invention: Sodium dodecyl sulfate (CAS 151-21-3) = 0.75% w/v (26 mM) Sodium lactate (CAS 867-56-1) = 0.051% w/v (10 mM) Lactic acid (CAS 79-33-4) = 0.216% w/v Sodium citrate (CAS 6132-04-3) = 0.06% w/v (2 mM) [00119] The pH value was measured at 3.5. The formulation was dispensed into 2 mL volumes and was stored at room temperature (10-30°C). Example 3: Morphology of SARS-CoV-2 [00120] SARS-CoV-2 has a structure as illustrated in Figure 1, which includes a lipid envelope (E) 10 and three structural proteins: spike glycoprotein (S) 20, membrane protein (M) 30, and nucleocapsid (N) 40; as well as RNA 50 and hemagglutinin esterase-dimer (HE) 60. The overall virus is approximately 100 nm in size. Viral entry into host cells is mediated by spike glycoprotein 20. [00121] Sodium dodecyl sulfate (SDS) disrupts the lipid envelope (E) 10, and binds to both membrane and non-membrane proteins. SDS binding is also cooperative so binding
of one monomer encourages the binding of more. Detergent monomers then solubilize the membrane proteins by partitioning into the membrane bilayer. See Figure 2. [00122] SDS’s sulphate region disrupts non-covalent bonds and the hydrocarbon tail dissolves hydrophobic regions in the structural proteins causing them to lose their conformational shape and function. The formulation is also at a low pH (3.5) and acid- induced protein unfolding of effected salt bridges and hydrogen bonds typically occurs at pH values < 5. S protein alteration by denaturation in an SDS / low pH environment renders the virus unable to bind to host cells. [00123] SDS at low pH (below pH 4) is shown to reduce the critical micellar concentration (CMC), which encourages micelles to form at a lower concentration than normal. Micelles are more stable the further they are away from their CMC. Hydrogen ions may decrease electrostatic repulsion of the charged SDS heads by decreasing the charge density on the surface of the micelle, changing the micelle’s stability. This means complexes formed in Figure 2 are likely to be formed and then stabilise over time. The SDS / low pH combination also denatures the three other structural proteins E, M and N. Additionally, the SDS dissolves the lipid envelope that encapsulates the genetic material, thereby resulting in inactivation of the virus. [00124] Viral RNA is preserved in the formulation by a combination of lower pH and sodium citrate. Without wishing to be bound by theory, it is thought that the sodium ions create a temporary attraction between sodium and the phosphate backbone of RNA. RNA is most stable around pH 4. The RNA is temporarily neutralized and sodium citrate in solution also acts as a strong chelating agent, thereby preventing oxidation and inactivating metal ion-dependent nucleases which would otherwise degrade the target RNA. Example 4: Inactivation of SARS-CoV-2 [00125] A high titre stock of the SARS-CoV-2 strain England/2/2020 was spiked into the formulation of Example 2. The stock of virus has a titre of 2.5 x 107 pfu/mL. A viral plaque assay was then conducted on Vero E6 cells, along with a triple passaging assay on Vero V1 cells. No virus was detected in either assay. Example 5: SARS-CoV-2 RNA stability study [00126] Tubes containing the formulation of Example 2 were spiked with a high titre stock of the SARS-CoV-2 strain England/2/2020. The tubes were then stored for five days at room temperature followed by five days in the refrigerator. PCR was conducted throughout to determine stability of viral RNA in the medium. Over the 10-day storage period, there was no significant difference in cycle threshold value for N gene, S gene or
ORF1a gene (all values were within 1 CT of time 0), thus indicating no significant degradation of RNA over time. Example 6: Human RNA stability study [00127] Three tubes were prepared containing the formulation of Example 2. The tubes were spiked with 8 µL of total human RNA that had been previously diluted 1:10 with purified water. The tubes were run through extraction using the MagMAX VP NAI II Kit on a KingFisher Flex system. The elution from each extraction was run once each on real- time PCR using the TaqPATH master mix and ACTB TaqMan primers and probes. The tubes of the formulation + RNA were then moved to a 30°C incubator. The tubes were sampled again at 3 days. At this time 250 µL aliquots were refrigerated at 4°C. The sample tubes were replaced in the 30°C incubator and sampled again at the 5 day timepoint before being moved into the refrigerator. The aliquots taken previously were sampled after 3 days in the refrigerator, and the sample tubes were sampled after 6 days in the refrigerator. [00128] Table 2: Results from RNA stability study (a) Time 0 RNA Stability
(b) 3 days at 30°C RNA Stability
(c) 5 days at 30°C RNA Stability
(d) 3 days at 30°C + 3 days at 2-8°C RNA Stability
(e) 5 days at 30°C + 5 days at 2-8°C RNA Stability
[00129] At all timepoints (a) to (e) the formulation showed <1 CT difference when compared to Time 0, indicating no significant degradation of RNA over time.
Claims
CLAIMS 1. An aqueous formulation for inactivating a pathogen, the aqueous formulation comprising: an anionic surfactant in a concentration of from about 15 mM to about 70 mM; a polynucleotide stabiliser in a concentration of from about 1 mM to about 200 mM; and a buffer providing a pH of from about 2 to about 4.2.
2. The aqueous formulation of any preceding claim, wherein the anionic surfactant is present in a concentration of from about 20 mM to about 30 mM.
3. The aqueous formulation of any preceding claim, wherein the anionic surfactant is present in a concentration of about 26 mM.
4. The aqueous formulation of any preceding claim, wherein the anionic surfactant is selected from alkyl sulfates, alkyl ether sulfates, arylalkyl sulfates, alkyl aryl ether sulfates alkyl ester sulfates, alkyl sulfonates, alkyl ether sulfonates, arylalkyl sulfonates, alkyl aryl ether sulfonates, alkyl ester sulfonates, alkyl α-olefin sulfonates, alkyl phosphates, alkyl ether phosphates, arylalkyl phosphates, alkyl aryl ether phosphates, alkyl ester phosphates, alkyl carboxylates, alkylamido carboxylates, alkyl ether carboxylates, arylalkyl carboxylates, alkyl aryl ether carboxylates, and alkyl ester carboxylates.
5. The aqueous formulation of any preceding claim, wherein the anionic surfactant is a C4-24 alkyl sulfate, optionally wherein the anionic surfactant is a C8-18 alkyl sulfate.
6. The aqueous formulation of any preceding claim, wherein the anionic surfactant is selected from: sodium dodecyl sulfate, sodium octyl sulfate, sodium 2-butyloctyl sulfate, sodium 2-ethylhexyl sulfate, sodium 3,7-dimethyloctyl sulfate, sodium lauryl sulfate, sodium lauryl sarcosinate, ammonium lauryl sulfate, sodium laureth sulfate, ammonium laureth sulfate, sodium myreth sulfate, sodium pareth sulfate, C14-16 alkyl α-olefin sulfonate, sodium dodecylbenzene sulfonate, sodium octanesulfonate, sodium decanesulfonate, sodium nonanesulfonate, sodium heptanesulfonate, sodium hexanesulfonate, sodium pentanesulfonate, sodium butanesulfonate, sodium stearate, dioctyl sodium sulfosuccinate.
7. The aqueous formulation of any preceding claim, wherein the anionic surfactant is sodium dodecyl sulfate.
8. The aqueous formulation of any preceding claim, wherein the formulation has a pH of at least about 3, optionally a pH of at least about 3.3.
9. The aqueous formulation of any preceding claim, wherein the formulation has a pH of from about 3 to about 4.
10. The aqueous formulation of any preceding claim, wherein the formulation has a pH of about 3.5.
11. The aqueous formulation of any preceding claim, wherein the buffer in a concentration of from about 1 mM to about 500 mM; optionally wherein the buffer is at a concentration of from about 5 mM to about 150 mM, optionally wherein the buffer is at a concentration of from about 5 to about 100 mM, further optionally wherein the buffer is at a concentration of about 10 mM.
12. The aqueous formulation of any preceding claim, wherein the buffer comprises or is selected from: lactate/lactic acid, glycine – hydrochloric acid and acetate/acetic acid.
13. The aqueous formulation of any preceding claim, wherein the buffer system comprises or is lactate/lactic acid, optionally wherein the lactate is sodium lactate.
14. The aqueous formulation of any preceding claim, wherein the polynucleotide stabiliser is citrate in a concentration of from about 1 mM to about 150 mM.
15. The aqueous formulation of claim 14, wherein the citrate is present in an amount of about 1 to about 3 mM; optionally wherein the citrate is present in an amount of about 1.2 mM to about 2.8 mM, further optionally wherein the citrate is present in an amount of about 1.5 mM to about 2.5 mM.
16. The aqueous formulation of any preceding claim, wherein the citrate is present in an amount of about 2 mM.
17. The aqueous formulation of any preceding claim, wherein the citrate is sodium citrate.
18. The aqueous formulation of any preceding claim, wherein the aqueous formulation is non-hazardous.
19. Use of an aqueous formulation of any preceding claim for the inactivation of a pathogen, optionally wherein the use further comprises the preservation of pathogen polynucleotides.
20. Use of the formulation of any of claims 1 to 18 for the preservation of pathogen polynucleotides, optionally wherein the polynucleotide is RNA or DNA.
21. The use of claim 19 or claim 20, wherein the pathogen is a virus or a bacterium.
22. The use of any of claims 19 to 21, wherein the pathogen is an enveloped or non- enveloped virus.
23. The use of claim 22, wherein the enveloped or non-enveloped virus is selected from: coronaviruses, rotaviruses, noroviruses, enteroviruses, hepatitis viruses, herpesviruses, papillomaviruses, arboviruses (e.g. West Nile virus, Zika virus, Dengue virus), ebolaviruses, orthomyxoviruses, paramyxoviruses, rabies virus, parechovirus, or rubella virus.
24. The use of claim 22 or claim 23, wherein the enveloped virus is a coronavirus.
25. The use of any of claims 19 to 24, wherein the pathogen is selected from: severe acute respiratory syndrome coronavirus (SARS-CoV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Middle East respiratory syndrome coronavirus (MERS-CoV), human coronavirus OC43 (HCoV-OC43), human coronavirus HKU1 (HCoV-HKU1), human coronavirus 229E (HCoV-229E), and human coronavirus NL63 (HCoV-NL63).
26. The use of any of claims 19 to 21, wherein the pathogen is a bacterium; optionally wherein the bacterium is selected from a Clostridium, a Pseudomonas, an Escherichia, a Klebsiella, an Enterococcus, an Enterobacter, a Serratia, a Stenotrophomonas, an Aeromonas, a Morganella, a Yersinia, a Salmonella, a Proteus, a Pasteurella, a Haemophilus, a Citrobacter, a Burkholderia, a Brucella, a Moraxella, a Mycobacterium, a Streptococcus, a Chlamydia, a Mycoplasma, a Bordatella, a Listeria, a Bacillus, a Francisella, a Neisseria, a Shigella, a Campylobacter, a Fusobacterium, a Legionella, a Helicobacter, a Streptococcus, or a Staphylococcus.
27. A method of inactivating a pathogen, the method comprising contacting a sample containing the pathogen with a formulation of any of claims 1 to 18.
28. A solid mixture comprising: an anionic surfactant in an amount of from about 50% to about 70% by weight; a buffer in an amount of from about 20% to about 30% by weight; and a polynucleotide stabiliser in an amount of from about 2% to about 20% by weight.
29. The solid mixture of claim 28, wherein the anionic surfactant is in an amount of about 70% by weight.
30. The solid mixture of claim 28 or claim 29, wherein the buffer is in an amount of about 25% by weight.
31. The solid mixture of any of claims 28 to 30, wherein the buffer is formulated to provide a pH of from about 2 to about 4.2 when the solid mixture is solubilised in water to provide an aqueous solution with the buffer at a concentration of from about 25 mM to about 150 mM.
32. The solid mixture of any of claims 28 to 31, wherein the polynucleotide stabiliser is citrate in an amount of from about 2% to about 10% by weight; optionally wherein the citrate is in an amount of about 5% by weight.
33. A method of identifying a pathogen, comprising: contacting a sample containing a suspected pathogen with an aqueous formulation of any of claims 1 to 18 to provide a sample solution comprising suspected pathogen nucleic acid; storing and/or transporting the sample solution; separating the suspected pathogen polynucleotides from the solution; and subjecting the suspected pathogen polynucleotides to a detection process, and identifying said suspected pathogen, if present, based on the detected pathogen polynucleotides.
34. A kit comprising: a container comprising an aqueous formulation of any of claims 1 to 18 or a solid mixture of any of claims 28 to 32; and optionally a sterile swab and/or funnel.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB2107439.8A GB2607285A (en) | 2021-05-25 | 2021-05-25 | Formulation |
GB2107439.8 | 2021-05-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022248858A1 true WO2022248858A1 (en) | 2022-12-01 |
Family
ID=76637751
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2022/051328 WO2022248858A1 (en) | 2021-05-25 | 2022-05-25 | Formulation |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB2607285A (en) |
WO (1) | WO2022248858A1 (en) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992009260A1 (en) * | 1990-11-28 | 1992-06-11 | Microcide, Inc. | Disinfecting and sanitizing compositions |
US5973137A (en) * | 1996-02-13 | 1999-10-26 | Gentra Systems, Inc. | Low pH RNA isolation reagents, method, and kit |
WO2006062835A2 (en) | 2004-12-09 | 2006-06-15 | The Dial Corporation | Compositions having a high antiviral and antibacterial efficacy |
US8293467B2 (en) | 2007-10-01 | 2012-10-23 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection and transport system and methods of use |
US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
US20190090483A1 (en) * | 2017-09-26 | 2019-03-28 | Ecolab Usa Inc. | Acid/anionic antimicrobial and virucidal compositions and uses thereof |
CN111676216A (en) * | 2020-06-18 | 2020-09-18 | 合肥铼科生物科技有限公司 | Extraction-free inactivated virus sample nucleic acid preservation solution and preparation method and application thereof |
CN111363729B (en) * | 2020-03-12 | 2021-04-16 | 苏州白垩纪生物科技有限公司 | RNA virus inactivation preservation solution and application thereof |
JP2021066697A (en) * | 2019-10-25 | 2021-04-30 | 花王株式会社 | Virus deactivator composition |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8080645B2 (en) * | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
CA2868805C (en) * | 2012-03-28 | 2018-09-04 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for the collection and isolation of nucleic acids from biological specimens |
-
2021
- 2021-05-25 GB GB2107439.8A patent/GB2607285A/en not_active Withdrawn
-
2022
- 2022-05-25 WO PCT/GB2022/051328 patent/WO2022248858A1/en active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992009260A1 (en) * | 1990-11-28 | 1992-06-11 | Microcide, Inc. | Disinfecting and sanitizing compositions |
US5973137A (en) * | 1996-02-13 | 1999-10-26 | Gentra Systems, Inc. | Low pH RNA isolation reagents, method, and kit |
WO2006062835A2 (en) | 2004-12-09 | 2006-06-15 | The Dial Corporation | Compositions having a high antiviral and antibacterial efficacy |
US8293467B2 (en) | 2007-10-01 | 2012-10-23 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection and transport system and methods of use |
US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
US20190090483A1 (en) * | 2017-09-26 | 2019-03-28 | Ecolab Usa Inc. | Acid/anionic antimicrobial and virucidal compositions and uses thereof |
JP2021066697A (en) * | 2019-10-25 | 2021-04-30 | 花王株式会社 | Virus deactivator composition |
CN111363729B (en) * | 2020-03-12 | 2021-04-16 | 苏州白垩纪生物科技有限公司 | RNA virus inactivation preservation solution and application thereof |
CN111676216A (en) * | 2020-06-18 | 2020-09-18 | 合肥铼科生物科技有限公司 | Extraction-free inactivated virus sample nucleic acid preservation solution and preparation method and application thereof |
Non-Patent Citations (12)
Title |
---|
"Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products", WHO TECHNICAL REPORT, 2004 |
"Transport Media Safety Risk - Use Compatible Transport Media with SARS-CoV-2 Tests that Use Bleach - Letter to Clinical Laboratory Staff and Health Care Providers", U.S FOOD AND DRUG ADMINISTRATION, 6 April 2020 (2020-04-06) |
A. ANANDANA. VRIELINK: "I. Moraes, The Next Generation in Membrane Protein Structure Determination", vol. 922, 2016, SPRINGER, article "Detergents in Membrane Protein Purification and Crystallisation", pages: 13 - 28 |
CURRO PROTOC. MICROBIOL., vol. 37, 2015 |
E. J. MENDOZA ET AL., CURR. PROTOC. MICROBIOL., vol. 57, 2020, pages 1 |
E. PATTERSON ET AL., THE JOURNAL OF INFECTIOUS DISEASES, vol. 222, 1 November 2020 (2020-11-01), pages 1462 - 1467 |
G. KAMPF ET AL., JOURNAL OF HOSPITAL INFECTION, vol. 105, 2020, pages 348 - 349 |
H.F. FLORINDO, NAT. NANOTECHNOL, vol. 15, 2020, pages 630 - 645 |
M.E.R. DARNELL ET AL., J. VIROL. METHODS, vol. 121, no. 1, October 2004 (2004-10-01), pages 85 - 91 |
N. BRACCI ET AL., PEERJ, vol. 8, 2020, pages 10639 |
R. BOOM ET AL., JOURNAL OF CLINICAL MICROBIOLOGY, vol. 28, no. 3, 1990, pages 495 - 503 |
S. J. SMITHER ET AL., JOURNAL OF VIROLOGICAL METHODS, vol. 193, 2013, pages 565 - 571 |
Also Published As
Publication number | Publication date |
---|---|
GB2607285A (en) | 2022-12-07 |
GB202107439D0 (en) | 2021-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10870878B2 (en) | Aqueous compositions that maintains fidelity of the nucleic acid sequences of a biological specimen | |
CA2985652C (en) | Rapid methods for the extraction of nucleic acids from biological samples | |
EP2535428B1 (en) | Biological specimen collection and transport system and methods of use | |
JP5904153B2 (en) | Sample preparation method for nucleic acid amplification reaction, nucleic acid amplification method, reagent for solid phase nucleic acid amplification reaction, and microchip | |
US10000742B2 (en) | Device and method of collection for RNA viruses | |
US11821029B2 (en) | Multipurpose compositions for collecting and transporting biological material | |
WO2020102570A1 (en) | Rna preservation solution and methods of manufacture and use | |
CN110938603A (en) | Universal virus sample preservation buffer solution and preparation method thereof | |
CA3207105A1 (en) | Multipurpose compositions for collecting and transporting biological material | |
WO2022248858A1 (en) | Formulation | |
AU2012211365B9 (en) | Biological specimen collection and transport system and methods of use | |
CA3171097A1 (en) | Products and methods for detection of viral nucleic acid | |
WO2022031992A1 (en) | Lysis buffer compositions and methods for preparing a viral biological sample useful for covid-19 testing | |
KR20230171989A (en) | Compositions and methods for storing biological samples | |
IE20210233A1 (en) | Compositions and methods for screening biological samples | |
AU2020348602B2 (en) | Multipurpose compositions for collecting and transporting biological material | |
US20210115498A1 (en) | Universal Transport Compositions and Systems | |
WO2017091809A1 (en) | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples | |
Esnault et al. | Optimisation of rapid untargeted nanopore DNA virus metagenomics using cell cultures and calves experimentally infected with bovine herpes virus-1 | |
Kubacki | A next generation sequencing approach for the diagnosis of outbreaks of emerging, mutated or novel viral pathogens | |
CN115927543A (en) | Liquefied combined product of viscous biological sample, nucleic acid amplification system, nucleic acid detection system, processing method and application | |
CN117867081A (en) | Broad-spectrum RNA sample preservation solution and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22731758 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22731758 Country of ref document: EP Kind code of ref document: A1 |